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ABSTRACT
Myotubularin related protein 2 (MTMR2) is a member of the myotubularin family
of phosphoinositide lipid phosphatases whose subcellular localization is regulated by a
phosphorylation event on Ser 58. Our laboratory has shown that the phosphorylationmimetic mutant (S58E) targets MTMR2 to the cytoplasm, whereas the phosphorylationdeficient variant MTMR2 (S58A) targets it to Rab5-positive endosomes resulting in
PI(3)P depletion. Although MTMR2 dephosphorylates PI(3)P and PI(3,5)P2, the
phosphoinositide binding proteins that are regulated by MTMR2 are poorly
characterized. In this study, we identified RME-8 as a novel PI(3)P binding protein
implicated in the translocation of Hsc70 to early endosomes for clathrin removal during
retrograde transport. Remarkably, the depletion of PI(3)P by MTMR2 S58A attenuated
RME-8 endosomal localization. Moreover, we have identified the amino acid
determinants required for PI(3)P binding within a region predicted to adopt a pleckstrin
homology-like fold in the N terminus of RME-8. The ability of RME-8 to associate with
PI(3)P and early endosomes is largely abolished when residues Lys17, Trp20, Tyr24, or
Arg26 are mutated resulting in diffuse cytoplasmic localization of RME-8 while
maintaining the ability to interact with Hsc70. We also provide evidence that RME-8
PI(3)P binding regulates the early endosomal clathrin dynamics and alters the steady state
localization of the cation independent mannose 6-phosphate receptor.
In addition, once a phosphorylation-deficient variant (S58A) targets MTMR2 to
Rab5-positive endosomes and depleting PI(3)P, it results in increased endosomal
signaling, such as a significant increase in ERK1/2 activation. Using in vitro kinase
assays, cellular MAPK inhibitors, siRNA knockdown and a phosphospecific-Ser58
VI

antibody, we provide evidence that ERK1/2 is the kinase responsible for phosphorylating
MTMR2 at position Ser58, which suggests that the endosomal targeting of MTMR2 is
regulated through an ERK1/2 negative feedback mechanism.
Taken together, our results suggest a model in which the localization of RME-8 to
endosomal compartments is spatially mediated by PI(3)P binding and temporally
regulated by MTMR2 activity and compartmentalization of MTMR2 and potential
subsequent effects on endosome maturation and endosome signaling are dynamically
regulated through MAPK-mediated differential phosphorylation events.
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CHAPTER 1
LITERATURE REVIEW
1.1. Protein Phosphorylation

One of the fundamental requirements of complex life is the need to respond
quickly to internal and external cues. To do so, cells have adapted strict and flexible
regulatory systems that are able to sense, transmit, store, and interpret information in
order to respond in a coordinated, organized and timely manner. Post translational
modifications (PTMs) are a major contributor to cellular responsiveness, due to their
ability to modulate the function of a protein in a rapid and reversible manner [2].
In particular, protein phosphorylation is one of the most pervasive PTM because
of its rapid reversibility and readily available phosphoryl group donor, ATP [3]. It is
arguably the most ubiquitous modification and regulates most cellular processes. The
addition and removal of a phosphoryl moiety on a protein is controlled by the action of
two groups of enzymes, kinases and phosphatases (Fig 1.1). Protein kinases catalyze the
covalent addition of a phosphate group to an amino acid in a peptide chain, while
phosphatases

catalyze

the

hydrolysis

of

phosphoproteins

[2].

Interestingly,

dephosphorylation or phosphorylation of an amino acid generates a new docking site for
intra or intermolecular bond formation leading to changes in protein conformation. This
action is reflected in alterations in protein-protein interactions, protein stability, enzyme
activity, and subcellular localization (Fig 1.2), thereby acting as a quick molecular
switch, capable of altering the behavior of its targets either directly or indirectly [2, 3].

1

On average about 30% of cellular proteins are phosphorylated [4, 5]. In
mammalian cells, phosphorylation usually occurs on serine, threonine and tyrosine
residues. However the majority of protein phosphorylation in eukaryotic cells occurs on
serine or threonine residues at about 84% and 15%, respectively. Interestingly tyrosine
phosphorylation is postulated to account for only 0.01% of the total protein
phosphorylation and yet it is essential in controlling normal cellular growth,
differentiation, metabolism, cell cycle, cell-cell communications, cell migration, gene
transcription, the immune response, and survival [5, 6].

Aberrant tyrosine

phosphorylation is linked with many human diseases such as diabetes, cancers,
rheumatoid arthritis, and hypertension [5].

Figure 1.1. Protein phosphorylation and dephosphorylation causes structural
changes of a protein and is regulated by the action of protein kinases and
phosphatases. From Zhang, Z. Y. (2003) Chemical and mechanistic approaches to the
study of protein tyrosine phosphatases, Accounts of chemical research. 36, 385-92 [7].

2

Figure 1.2. The rapid and reversible nature of protein phosphorylation serves as
molecular switches mechanism modulating this way many aspects of protein
function such as enzymatic activity, structural conformation, protein-protein
binding, subcellular localization, protein turnover, crosstalk with other PTMs. From
Humphrey, S. J., James, D. E. & Mann, M. (2015) Protein Phosphorylation: A Major
Switch Mechanism for Metabolic Regulation, Trends in endocrinology and metabolism:
TEM [2].
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1.2. Protein Phosphatase Superfamily

Kinases have been thought to control the amplitude of a signaling response,
whereas phosphatases to control its rate and duration. The concerted actions of these two
classes of enzymes are tightly coordinated in order to regulate cellular signaling [8-10].
Interestingly, almost all protein kinases share the same 3D structure because they derive
from one common ancestor [8, 11]. In contrast to kinases, protein phosphatases are a very
diverse family of proteins and have evolved into quite discrete families. Members of the
protein phosphatase family have adopted different 3D structure, with different active sites
and mechanisms of hydrolysis [11]. Approximately, there are about 200 phosphatase
genes [12], of which 100 are members of the Protein Tyrosine Phosphatase (PTP) family.
Protein Tyrosine Kinases (PTK) and PTP gene families contain 90 and 100 genes
respectively, which suggests that the level of complexity among these families is similar
[8]. One of the most striking features of PTPs is that the majority of them contain
combinations of regulatory modular domains other than the catalytic domain. Theses
non-catalytic regulatory and targeting domains are usually attached to the N and C
termini of the catalytic domain and generate a large diversity in the structural and
functional context within the PTPs [13, 14]. These are mostly characterized by proteinprotein or phospholipid binding modules [15].
Overall, there are 3 major families of protein phosphatases based on the sequence,
structure and catalytic mechanism that they have adopted; Ser/Thr phosphatases, PTPs
and Asp-based protein phosphatases [1]. All members of the PTP family contain the
CX5R signature motif within the active site and share a common catalytic mechanism,
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where the initiation of the reaction mechanism starts with the cysteine residue within the
signature motif acting as a nucleophile to attack the incoming phosphotyrosine of the
substrate. The unique microenvironment within the active site greatly aids the catalysis
reaction by lowering the pKa of the catalytic cysteine. Based on PTPs gene sequence and
structure, they are further classified into 3 evolutionary separate families: class I-PTPs
(cysteine based); class II-PTPs (cysteine based), class III-PTPs (cysteine based) PTPs,
(Fig. 1.3) [1, 16], although the vast majority of protein phosphatases belong to Class I
(cysteine based).
Based on secondary structure and sequence homology of the catalytic domain
class I-PTPs, are further subdivided additionally into the classical PTPs (both receptorlike and non-receptor PTPs), and the VH1-like phosphatase group, also known as dual
specificity phosphatases (DUSPs). The latter are not well conserved and have little
sequence similarity, outside the signature motif. Although, they share the same catalytic
mechanism as the classical PTPs, the active site cleft of DUSPs allows for the
accommodation of dually phosphorylated substrates, pSer/ pThr residues as well as pTyr
residues [8]. DUSPs consist of the following groups of enzymes: the MAP kinase
phosphatases (MKPs), the atypical DUSPs, the slingshots, the PRLs, the CDC14s, the
PTEN, and the myotubularins, (Fig. 1.3) [17-20]. Part of their heterogeneity originates
because they can hydrolyze various substrates, where besides protein hydrolysis, they can
also dephosphorylate RNA molecules as well as phosphatidylinositols [21, 22].

5

Figure 1.3. Classification of protein phosphatases. Adapted from Moorhead, G. B.,
Trinkle-Mulcahy, L. & Ulke-Lemee, A. (2007) Emerging roles of nuclear protein
phosphatases, Nature reviews Molecular cell biology. 8, 234-44 [1].
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1.3. Catalytic mechanism of protein tyrosine phosphatases

PTPs catalyze phosphate hydrolysis via a covalent thiol-phosphate intermediate
[7, 23]. The invariant cysteine residue of the CX5R signature motif located at the base of
the cleft is essential for catalysis. The unique microenvironment created within the active
site pocket lowers the pKa of the invariant cyteine that acts as a nucleophile in the
catalytic mechanism [5, 24, 25]. Besides the amino acids in the signature motif, other
residues located on the P-loop, the WPD loop and the Q-loop of the active site are also
critical for proper reaction. (Fig. 1.4) [25]. Structural studies of PTP1B, the first PTP
isolated, revealed that following substrate binding its active site undergoes a large
conformational change. In particular, WPD loop located on the sides of the active site,
closes around the side chain like a “flap” of the pTyr residue of the substrate. Closure of
the WPD loop positions an invariant aspartic acid residue (Asp181 in PTP1B), which
now donates its proton to the tyrosyl leaving group (in PTP1B is an Asp 181). In this
first step of the reaction, aspartic acid within the WPD loop acts as a general acid and
forms a thiol-phosphate intermediate, (Fig. 1.4 and 1.5). Meanwhile, in the second step
of the catalysis in PTP1B, an invariant glutamine (Gln 262 in PTP1B) located in the Q
loop, mediates the coordination of a water molecule. Interestingly, in the second step of
the reaction mechanism, the same invariant aspartic acid residue involved in step 1 (Asp
181 in PTP1B), now acts as a general base by activating a water molecule in the
hydrolysis of the phosphoenzyme intermediate, which in turn induces the release of the
phosphate group (Fig. 1.4).
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Interestingly, the active site depth varies among different subfamilies of PTPs
(Fig. 1.6). For instance the classical PTPs have a pronounced depth of the active site
cleft, which contributes to the absolute specificity towards pTyr-containing substrates
[26]. Smaller substrates such as phosphoserine and phosphothreonine residues can not
access the nucleophilic cysteine residue at the base of the cleft and as a result would not
be targeted for hydrolysis.
The general features of this mechanism are conserved throughout all the PTPs,
although the precise active site structural architecture changes slightly among
subfamilies. For instance, unlike the active site of classical p-Tyr specific phosphatases
that have a very deep cleft to accommodate long phosphotyrosine containing substrates,
DUSPs contain a much shallower cleft to accommodate a dually phosphorylated
substrate. Other members of the PTP family of proteins, such as in myotubularins, the
active site cleft is similar in depth to the classical p-Tyr specific phosphatases, but is
wider than both the classical p-Tyr specific phosphatases and DUSPs in order to
accommodate the sugar head group of the inositol phospholipid, (Fig. 1.6) [27].
However, unlike the other members of the PTP family, myotubularins do not have the
conserved acidic residue that resides in the WPD-loop of the classical PTPs. Instead, it
has an aspartic acid within the active site that plays the function of the general acid in the
first step of the catalysis [27].
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Figure 1.4. General mechanism of dephosphorylation employed by PTPs. From
Tonks, N. K. (2003) PTP1B: from the sidelines to the front lines!, FEBS Lett. 546, 1408.
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Figure 1.5. The architecture of the PTP1B active site. Upper panel displays in blue
ribbon the secondary structure elements of the catalytic domain of PTP. Within the
catalytic site the critical motifs are colored as the signature motif in yellow, the WPDloop in red, the Q-loop in green and the P-loop in orange. Lower panel displays a zoomed
in image of the active site and the critical amino acids necessary for catalysis. From
Tonks, N. K. (2003) PTP1B: from the sidelines to the front lines!, FEBS Lett. 546, 1408.
10

Figure 1.6. Comparison of the active site cleft of different members of the PTP
family. From Begley, M. J. & Dixon, J. E. (2005) The structure and regulation of
myotubularin phosphatases, Current opinion in structural biology. 15, 614-20.
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1.4. Myotubularin lipid phosphatases

The myotubularin (MTM) subfamily is one of the largest and conserved subfamily
of protein tyrosine phosphatases from yeast to humans [28-32]. The human MTM family
of phosphatases includes MTM1 and MTM-related proteins [28-30, 32]. The MTM
family consists of 15 members that have the characteristic phosphatase domain. Nine of
these family members possess a conserved active site motif CXXGWDR and hydrolyze
the D3 position of the lipid second messengers, phosphatidylinositol 3-phosphate and
phosphatidylinositol 3,5- biphosphate, PI(3)P and PI(3,5)P2 respectively [22, 28, 31, 3337]. The remaining six MTM proteins are catalytically inactive and have been shown to
regulate the activities of active phosphatases, also known as the ‘pseudophosphatases’
[28].
The catalytically active MTM proteins are divided into four groups based on their
structure: The MTM1 group consists of MTM1, MTMR1 and MTMR2; the MTMR3
group contains MTMR3 and MTMR4; the MTMR6 group contains MTMR6, MTMR7
and MTMR8; whereas the last group contains MTMR14 [27, 29]. All of the proteins
within the MTM1, MTMR3 and MTMR6 groups contain a PH-GRAM (pleckstrin
homology glucosyltransferases, Rab-like GTPase activators and myotubularins) domain
at the N-terminus and a coiled-coil domain near the C-terminus (Fig. 1.7) [37]. Proteins
within the MTM1 group contain a C-terminal PDZ-binding domain, whereas members of
the MTMR3 subgroup possess a C-terminal FYVE domain. Meanwhile, MTMR14
contains only the phosphatase domain. Uniquely, certain MTMs contain a SID sequence
[SET

(Suvar3-9,

Enhancer-of-zeste,

Trithorax)-interacting
12

domain]

within

the

phosphatase domain whose function is to mediate protein-protein interactions, (Fig. 1.7)
[37]. Besides the inactive phosphatase domain, the six inactive members of the MTM
family (MTMR5, MTMR9, MTMR10, MTMR11, MTMR12 and MTMR13) contain the
same major architectural features as the active members such as the PH-GRAM domain
and the C-terminal coiled-coiled domain.

Figure 1.7. The structural features of active myotubularins. From Sasaki, T.,
Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M. & Suzuki, A. (2009)
Mammalian phosphoinositide kinases and phosphatases, Progress in lipid research. 48,
307-43.
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1.5. Myotubularin related - 2

The loss of function mutation of the MTMR2 gene causes Charcot-Marie-Tooth
disease type 4B1 (CMT4B1), which is an autosomal recessive demyelinating neuropathy,
characterized by abnormally folded myelin sheaths [38, 39]. Studies in animal models
have demonstrated that Mtmr2-null mice develop azoospermia, as well as progressive
neuropathy particularly in the paranodes of Schwann cells [40]. Interestingly, the loss of
either MTMR2 or MTMR13 causes Charcot-Marie-Tooth type 4B1 and 4B2 neuropathy,
respectively [40-44]. In particular, MTMR2 is a ubiquitously expressed lipid phosphatase
whose physiological substrates are both PI(3)P and PI(3,5)P2. Studies have revealed that
once mutated, the levels of PI(3)P as well as PI(3,5)P2 are elevated [37, 45].
Both PI(3)P and PI(3,5)P2 derive from phosphatidylinositol (PI) which is the basic
building block for the intracellular inositol lipids in mammalian cells. They are composed
of D-myo-inositol-1- phosphate linked to 2 fatty acyls groups through a phosphate group
[46]. The inositol ring of PIs can be reversibly phosphorylated D3, D4 or D5 positions
and differential combination of phosphorylation on these positions can generate up to a
total of seven different species of PIs [47]. The fundamental function of these secondary
messengers is to recruit effector proteins with conserved modular protein domains to
precise membranous location at a precise time [46-50]. This ability to spatially and
temporally regulate location of effector proteins, makes these lipids absolutely critical
regulators of cellular signaling. Interestingly, the interconvertability of these
phospholipids is mediated and highly controlled by the action of lipid kinases and
phosphatases, (Fig 1.8) [47]. In a typical eukaryotic cell, PIs represents less than 15% of
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the total phospholipids. Since there is an abundance of PI(3)P compared to PI(3,5)P2 in a
typical cell (2-5% of PI(3)P vs 0.04% of PI(3,5)P2 of total PIs), our studies concentrate
on understanding the MTMR2 PI(3)P mediated cellular regulation. It is important to note
that each of the seven phosphoinositides has a specific subcellular distribution within the
cell. For instance, PI(3)P is predominantly located at the early endosomes, whereas
PI(3,5)P2 is enriched at the late endosomes [47]. Since CMT4B1 mutations cause a lossof-function mutation by reducing MTMR2’s ability to dephosphorylate PI(3)P and
PI(3,5)P2, it is thought that the alterations of its substrates may cause a disruption of
intracellular trafficking and membrane homeostasis, particularly in Schwann cells (ref).
Studies in our laboratory and others have demonstrated that phosphorylation of
lipid phosphatases plays a significant role in their regulation. For example, a
phosphorylation event on PTEN decreases its lipid phosphatase activity, which in turn
inhibits access to its substrate [51, 52]. Our laboratory has discovered a phosphorylation
event on Ser 58 of MTMR2 that is in close proximity to its PH-GRAM domain [53].
MTMR2 phosphorylation event alters its subcellular localization and thus access to its
physiological lipid substrate. Once MTMR2 is phosphorylated on Ser 58 it is sequestered
in the cytoplasm away from its physiological substrate. Conversely, dephosphorylated
MTMR2 is localized in proximity to its substrate, at the early endosomes. Once there,
MTMR2 triggers PI(3)P dephosphorylation and increases growth factor receptor
signaling pathways, such as the extracellular signal-regulated kinase (ERK) pathway.
This example demonstrates that phosphorylation serves as a molecular switch to control
MTMR2 access to its lipid substrate, and in this manner, controls downstream endosome
maturation events [53]. The role that MTMR2 plays in trafficking events remains poorly
15

understood, even though the pathophysiological consequences established from loss of
the MTMR2 function is very well established. Hence the investigation of the MTMR2
phosphorylation mechanism is important for understanding its spatial and temporal
functional regulation.

Figure 1.8. The metabolism of the seven isoforms of phosphatidylinositols. From
Cullen, P. J., Cozier, G. E., Banting, G. & Mellor, H. (2001) Modular phosphoinositidebinding domains--their role in signalling and membrane trafficking, Current biology :
CB. 11, R882-93.
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1.6. Endocytosis

Endocytosis is the process by which cells internalize the extracellular matrix,
small molecules, macromolecules, ligands and receptors along with parts of their plasma
membrane. Mammalian cells in particular, have adopted various mechanisms to
internalize cargo from the cell surface and ultimately target them at a precise cellular
location. Some of these mechanisms involve phagocytosis, pinocytosis, clathrindependent receptor-mediated endocytosis, and clathrin-independent endocytosis [54].
From all of the endosomal internalization mechanisms, receptor-mediated endocytosis via
clathrin-coated pits is by far the best-characterized pathway [54-57]. The underlying
mechanism of this process is becoming the focus of intense investigation in various
biological fields, since its malfunction has been shown to be the cause of many medical
conditions [58-61].
In receptor-mediated endocytosis, once ligands bind receptors, they concentrate in
clathrin-coated pits at the plasma membrane. Interestingly, prior to forming clathrincoated vesicles (CCV)s at the plasma membrane, clathrin and clathrin adaptor proteins
are first recruited to mediate the assembly of clathrin into lattice-like structures, which in
turn induces the inward curvature of the membrane [62].

This allows the pits to

eventually bud off and form clathrin-coated vesicles (CCV) with receptors still bound to
ligands. Following this, clathrin coat sheds off from the vesicles to fuse later on with the
early endosomes (EEs), once CCVs internalize. An early endosome is a very dynamic
vesicular structure, containing an extensive amount of tubules and is the site where
receptor-ligand complex dissociate due to its slightly acidic internal environment (Fig
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1.9) [63-65]. Following ligand-receptor dissociation, receptors selectively accumulate at
tubules of the early endosome, so they can be targeted back to the plasma membrane
through a recycling endosome. Typically, many of the receptors are re-used up to several
hundred times, whereas ligands are degraded following the late endosome-to-lysosomes
route [66-70]. In a similar manner, lysosomal enzymes accumulate at late endosomes and
lysosomes by the same pathway in order to maintain proper lysosomal biogenesis [71].
Lysosomes are small vesicles, where ligands are targeted for degradation via the
combined action of both lysosomal enzymes and acidic pH. Since, a plethora of medical
conditions have arisen due to an aberrant lysosomal biogenesis, many laboratories are
increasing their efforts to better understand the mechanism by which they are regulated
[72-75].
In addition to originating from the plasma membrane, CCVs can also originate
from the trans-Golgi network (TGN) and fuse with early endosomes. Some of the cargo
delivered at the early endosomes via this route include the newly synthesized lysosomal
enzymes which subsequently conclude their journey at the lysosomes [69]. Regardless of
whether clathrin-coated vesicles originate at the plasma membrane or the TGN, they
comprise a population of transport machineries that are specifically designed to fuse with
endosomes once clathrin is uncoated [55]. Overall, the endocytic pathway contains
functionally and physically discrete compartments, where the dissociation and sorting of
receptor and ligands occurs at the early endosomes and the accumulation and digestion of
macromolecules occurs at the late endosomes and lysosomes (Fig 1. 10) [69].
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Figure 1.9. An early endosome taken with a freeze-etch electron microscopy. From
Gruenberg, J. (2001) The endocytic pathway: a mosaic of domains, Nature reviews
Molecular cell biology. 2, 721-30.
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Figure 1.10. Endocytosis and endosomal maturation process. From Hu, Y. B.,
Dammer, E. B., Ren, R. J. & Wang, G. (2015) The endosomal-lysosomal system: from
acidification and cargo sorting to neurodegeneration, Translational neurodegeneration.
4, 18.
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1.7. Endosomal Retrograde Transport Pathway

Following endocytosis, the majority of cargos accumulate at the early endosomes
to then get sorted into their final intracellular destinations. Some cargo recycle back to
the plasma membrane [70], whereas others are targeted for degradation to late
endosomes/lysosomes [76]. Recent studies have started to characterize another
endosomal vesicular transport pathway, called the endosomal retrograde transport. It can
selectively target certain cargo to escape the early endosome to-lysosome degradation
pathway and translocate to the trans-Golgi network (TGN). This pathway in particular
was first discovered in 1998 and to this day remains a poorly explored cellular process
[77, 78]. Some of the cargo that get sorted by the retrograde transport pathway include
sortilins, wntless receptors, signaling molecules such as EGF receptor, viruses and
pathogenic products from bacteria such as toxins. Nonetheless, the best characterized
retrograde transport cargo proteins are the cation-independent mannose 6-phosphate
receptors (CI-MPR)s [79].
CI-MPRs are type I transmembrane proteins that recognize the newly synthesized
acid hydrolases tagged with a mannose 6-phosphate group at the TGN. Once CI-MPRs
bind mannose 6-phosphate tagged acid hydrolases, clathrin adaptor proteins such as GGA
and API-1 signal adaptor proteins at the TGN bind the cytosolic tail of CI-MPRs [80].
These interactions allow for the capture of the CI-MPR-ligand complexes into clathrincoated vesicles, which then fuse with an early endosomes once clathrin is uncoated. The
acidic pH of the early endosomes induced the release of the acid hydrolases into the early
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endosomes lumen, from where they are transported back to the late endosomes and
eventually to the lysosomes. In contrast to the ligands, the unoccupied CI-MPR receptors
embedded in the early endosomes membranes recycle back to TGN via retrograde
transport for further rounds of acid hydrolase sorting (Fig. 1.10) [79].
The retrieval of CI-MPRs from the early endosomes to TGN via retrograde
transport is mediated through the action of a heteropentameric protein complex that
associates with the cytosolic face of endosomes called retromer [81]. The mammalian
retromer complex is composed of two major subunits, the sorting nexin dimer composed
of SNX1/SNX2 and trimer composed of Vps26, Vps29 and Vps35, which serve as the
cargo recognition unit. Recent studies have implicated retromer in a broad range of
physiological, developmental and pathological processes, highlighting the critical nature
of retrograde transport mediated by this complex [82].
In addition to retromer coat, there is a growing body of evidence that suggests
clathrin also has a role in retrograde trafficking, particularly in retromer biology [83-87].
A valuable tool in understanding the role of retromer and clathrin in retrograde
trafficking is the trafficking of the bacterial protein toxin Shiga toxin (STx) and CI-MPR
[83]. For instance, STx is capable of taking over the cells endocytic and retrograde
machinery to allow efficient uptake and retrograde trafficking to the TGN via retromer
[84]. Once the function of clathrin is perturbed, STxB results in failure of the B subunit
of STx (STxB) to traffic to the TGN, instead it is targeted on subdomains of early
endosome and gets stalled [84]. Besides clathrin, it has also been shown that
perturbations of retromer subunit VPS26 results in a nearly complete block of STxB
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retrograde trafficking [84], indicating that retromer and clathrin coats act on a similar
pathway.
Recently, it has been demonstrated that retromer regulates endosomal clathrin
dynamics via the DnaJ domain protein RME-8/Hsc70 chaperone complex [83, 86].
Although, the mechanism by which RME-8/Hsc70 dissociates clathrin is unknown, other
DnaJ containing proteins such as auxilins are known to play a role in uncoating of CCVs
at both the plasma membrane and TGN (48). Following direct binding to clathrin, they
recruit Hsc70 to CCVs enabling the uncoating of CCVs by breaking clathrin heavy
chains interactions [83, 86, 88].
RME-8 was first discovered in 2001 utilizing a genetic screen in C. elegans to be
involved in the process of endocytosis [89].

Following this, studies in Drosophila

discovered RME-8 to be specifically involved in the receptor-mediated endocytosis and
predominantly found to be present at the early endosomes [62, 90]. Remarkably, RME-8
co-localizes and directly binds quite strongly to SNX1 at early endosomes [83, 86]. The
importance of RME-8’s function in endosomal vesicular traffic was brought to light once
it was observed to be involved in retromer-mediated retrograde trafficking of cargo such
as CI-MPR, STxB and wntless receptors [83, 86]. To note is the fact that RME-8 and
Hsc70 roles in retrograde transport are tightly associated with each other; for example
perturbation of either Hsc70 or RME-8 resulted in the same phenotype [83, 86].
Moreover, the knock down of SNX-1, RME-8 or Hsc70 alters clathrin dynamics,
translocating it from the cytoplasm to the endosomes leading to an endosomal clathrin
accumulation [87].
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Figure 1.11. Sorting of the acid hydrolases via mannose 6-phosphate receptors.
Adapted from Bonifacino, J. S. & Hurley, J. H. (2008) Retromer, Curr Opin Cell Biol.
20, 427-36.
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1.8. Objectives
The objective of my thesis is to study mechanistic aspects of MTMR2
phosphorylation and effects on downstream endosomal maturation and signaling. In
particular, a major focus of my work has been centered in discovering MTMR2 targets
whose function depends on PI(3)P levels and thus would represent potential novel
biomarkers or therapeutic targets for CMT4B1 disease.
Specifically we aim to:
1. Identify and characterize novel PI(3)P binding proteins that are regulated by
MTMR2.
2. Identify the mechanism by which MTMR2 reversible phosphorylation
regulates endosomal trafficking events.
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CHAPTER 2
RECEPTOR MEDIATED EDOCYTOSIS 8 IS A NOVEL PI(3)P BINDING
PROTEIN REGULATED BY MYOTUBULARIN RELATED -2

2.1. Introduction

The phosphatidylinositol phosphate (PIP) isoforms PI(3)P and PI(3,5)P2 are
known to serve as membrane targeting ligands for proteins that are essential for cellular
membrane trafficking processes.

These lipid-protein interactions function in

translocating signaling proteins to discrete membrane locations where they can properly
respond to extracellular stimuli [47]. The signaling pathways are subsequently turned off
through the dephosphorylation of the PIPs.
The MTMR family of lipid phosphatases, composed of active and inactive
subgroups, represents the largest protein tyrosine phosphatase subfamily conserved from
yeast to humans [29, 32]. Initially, MTM1 was the first family member shown to
dephosphorylate the D3 position of PI(3)P in vitro and in cellula [22, 91]. Subsequently,
all active members tested have been shown to also be PI(3)P phosphatases [34, 36].
Furthermore, there is accumulating evidence that MTMs can also utilize PI(3,5)P2 as a
physiologic substrate [36, 92, 93]. Therefore, MTMs are thought to antagonize effector
molecules that utilize PI(3)P or PI(3,5)P2 as targeting ligands and/or allosteric activators.
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Mutations in mtmr2, on chromosome 11q22, have been shown to cause the
neurodegenerative disorder, Charcot-Marie-Tooth disease 4B1 (CMT4B1) [40].
CMT4B1 is an autosomal recessive aggressive form of CMT, characterized by
abnormally folded myelin sheaths, inadequate nerve signaling to muscles, and eventual
muscle weakness and atrophy [44]. While the pathophysiological consequence resulting
from the loss of MTMR2 function is well established, how MTMR2 participates in
trafficking events remains poorly understood. Recently we have characterized an Nterminal MTMR2 phosphorylation site at position Ser58 that dramatically regulates
MTMR2 endosomal localization and thus access to its lipid substrates [53].

A

phosphorylation deficient variant (MTMR2 S58A) displays strong endosomal
localization and an enhanced ability to deplete PI(3)P from endosomal vesicles signifying
that reversible phosphorylation is a critical mechanism regulating the activities of
MTMR2.
The biological pathways affected by MTMR proteins remain inadequately
characterized. This task has proven difficult due to the poor understanding of PIP
binding domains that specifically interact with the PIP isoforms that MTMRs target [47].
In this study, we utilized a proteomic approach using immobilized PIP isoforms to
identify novel PIP binding proteins. Herein, we describe the identification of receptor
mediated endocytosis 8 (RME-8) as a novel PI(3)P binding protein whose lipid binding
activity is affected by MTMR2.
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2.2. Materials and Methods

2.2.1. Identification of novel PIP binding proteins by mass spectrometry

Immobilized PIP isoforms (Echelon) were prepared for affinity chromatography
according to the manufacturer’s protocol. RT4-D6P2T Schwann cells (6 x 107) were
grown to 80% confluency, lysed and the soluble lysate filtered. The cellular lysates was
pre-cleared with PI control beads followed by the loading of 10 mg of total protein to
either PIP, PI(3)P, PI(3,5)P2, or PI(5)P resin. The lipid pulldown was performed by batch
method overnight at 4° C. Following rigorous washing conditions the bound proteins
were eluted in SDS/PAGE loading buffer and analyzed by SDS/PAGE and silver
staining. Protein bands of interest were excised and in-gel digested with trypsin. The
extracted pools of tryptic peptides were then analyzed by MALDI-TOF mass
spectrometry (MS) for protein identification as described previously [94].

2.2.2. Cell culture and transfection

HeLa and HEK293 cells were utilized for their reproducible transfection
efficiency and were maintained in DMEM/ F-12 supplemented with 10 % FBS, 1%
penicillin/streptomycin and maintained at 37° C with 5 % CO2. Cells were transiently
transfected with expression vectors encoding FLAG tagged-MTMR2 S58A [53] and
GFP-RME-8 variants [90] using FuGene HD Transfection Reagent (Roche ) according to
the manufacturer’s protocol.

The DsRed-FYVE construct was created by PCR

amplification of the sequence encoding the FYVE domain of EEA1 followed by cloning
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into the pDsRed expression vector (Clonetech). Where indicated, wortmannin treatment
(1 µM) was for 1h at 37 °C.

2.2.3. PIP pulldown

HEK293 cells were transiently transfected with GFP-RME-8 variants for 24 hrs
and lysed in modified RIPA buffer (50mM Tris-HCl pH 7.4, 1% Nonidet P-40, 76 mM
NaCl, 2 mM EGTA, 10% Glycerol) supplemented with protease inhibitors PMSF (1 mM)
and aprotinin (1 mM). Cell lysates were incubated with PI(3)P, PI(3,5)P2 and PIP
conjugated resin (Echelon Research Laboratories) overnight at 4 °C. The samples were
washed 3 times with 10 mM HEPES pH 7.4, 150 mM NaCl, 0.25% NP-40 and
resuspended in SDS/PAGE loading dye. The protein samples were separated on an 8%
SDS/PAGE, transferred to a PVDF membrane and immunoblotted with goat anti-GFP
(Rockland) as the primary antibody and rabbit-anti goat HRP (Rockland) as the
secondary antibody. Proteins were visualized using Super Signal West Femto reagent
(Thermo scientific).

2.2.4. Immunoflourescence and image acquisition

Following transient transfection, Hela cells were fixed at room temperature with
3.7% paraformaldehyde in PBS. Cells were then permeabilized with 0.15% Triton X-100
in PBS at room temperature for 2 min and blocked for 1 hr in 5% BSA (Sigma). Cells
were incubated with mouse anti-FLAG antibody (Sigma Aldrich) or rabbit anti-EGFR

37

(Santa Cruz Biotechnology) in TBST. Following washing, cells were incubated with
either Alexa 568 goat anti-mouse, Alexa 350 donkey anti-rabbit (Invitrogen) or
fluorescein goat anti-rabbit (Vector laboratories) secondary antibodies. All the
incubations were performed at room temperature for 1 hr followed by three 5 min washes
in TBST. Hoechst 33342 (Molecular Probes) was used to stain the nuclei and Slowfade
Antifade kit was used to mount the slides (Molecular Probes) according to the
manufacturer’s protocol. Images were captured with a Q-imaging CCD camera on a
Leica DMIRB microscope using the Northern Eclipse software and Abobe Photoshop
7.0.

2.3. Results and Discussion

2.3.1. Isolation of the RME-8/HSC70 complex from Schwann cells using PI(3)P affinity
chromatography.

Knowledge of proteins affected by the lipid phosphatase activity of MTMR2 is
poorly defined.

To identify putative targets of MTMR2, a pull down assay was

performed using disease relevant Schwann cells and conjugated PI(3)P and PI(3,5)P2
beads. Beads conjugated with the enzymatic products of MTMR2, PI and PI(5)P, were
also included. The PIP beads were incubated with equal concentrations of cellular lysate
from rat RT4-D6P2T Schwann cells followed by extensive washing. Following elution
in SDS/PAGE loading dye, the proteins were separated by SDS/PAGE and detected by
silver staining (Fig. 1). Several protein bands appeared specific to the PIP isoforms
including two protein bands observed at molecular weights of approximately 205 kDa
and 70 kDa that were specific for PI(3)P and PI(3,5)P2 (indicated by asterisks).
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Figure 2.1. PIP lipid pull down from Schwann cells. Cell lysates were prepared from
rat RT4-D6P2T Schwann cells (6 x 107). Approximately 10 mg of total protein was
subjected to affinity chromatography on the indicated immobilized PIP resin. Following
stringent washing conditions, the samples were resolved on a 12% SDS-PAGE gel and
silver stained. Asterisks indicate the protein bands of interest which were excised and
identified by mass spectrometry.
Protein bands of interest were excised and in-gel
digested with trypsin. The extracted pools of tryptic peptides were then analyzed by
MALDI-TOF MS/MS for protein identification. The 205 kDa band was identified as
receptor-mediated endocytosis 8 (RME-8) and the 70 kDa band was identified as heat
shock cognate 70 (Hsc70) (Fig. 2). At least 10 peptides from each trypsin digest were
subjected to MS/MS analysis to obtain unambiguous identification. The high sequence
coverage was particular important in the case of Hsc70 in order to distinguish from
closely related homologues. Notably, the 200 kDa band present in the PI(5)P sample
(Fig. 1) was identified as pyruvate decarboxylase (data not shown).
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Figure 2.2. Identification of putative PIP binding proteins by MALDI-MS/MS.
Following trypsin digestion the peptides were analyzed by MALDI-MS/MS for protein
identification. (A) Shown is a MS/MS spectrum for the precursor ion 1957 m/z. Fragment
ion series analysis resulted in identification of a sequence found in RME-8. (B) Shown is
a MS/MS spectrum for precursor ion 1691 m/z. Fragment ion series analysis resulted in
identification of a sequence found in Hsc70.
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The identification of RME-8 and Hsc70 is intriguing since these two proteins in a
variety of organisms and cell types have been shown to function in a complex and
regulate receptor-mediated and fluid-phase endocytosis [62, 89, 95]. Furthermore,
Drosophila RME-8 and Hsc70 have been shown to interact in vitro [62], while human
RME-8, through its J-domain, has been shown to directly bind to Hsc70 in an ATP
dependent manner [95].

2.3.2. PI3P is required for the association between RME-8 and early endosomes

It has been demonstrated that RME-8 can localize to membrane vesicles including
early endosomes [83, 90]. Our current proteomic results suggest that RME-8 can also
interact with the substrates of MTMR2, such as PI(3)P, which are present on membrane
vesicles such as endosomes. To test if PI(3)P is required for its endosomal localization,
we examined the ability of RME-8 to co-localize with a well characterized reporter for
PI(3)P

enriched

endosomes,
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DsRed-FYVE

[96].

Figure 2.3. Rme-8 colocalizes with vesicles containing PI(3)P. Hela cells were cotransfected with GFP-RME-8 and DsRed-FYVE expression vectors and analyzed by
immunofluorescence microscopy. Localization pattern of GFP-RME-8 without
wortmannin treatment (A) and with wortmannin treatment (B) is shown. The merged
images are depicted in the right panel showing partial overlap of GFP-RME-8 and
DsRed-FYVE localization without wortmannin treatment and dispersed localization with
wortmannin treatment. Images were taken with 40X objective using a fluorescence
microscope. Bars, 15 µm.
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As shown in Fig. 2.3A, RME-8 displayed strong co-staining with DsRed-FYVE
confirming that RME-8 positive vesicles contain PI(3)P. Cells were then treated with the
phosphoinositide 3-kinase (PI(3)K) inhibitor wortmannin to investigate the requirement
of PI(3)P for the membrane vesicle localization of RME-8. Wortmannin-induced PI(3)P
depletion led to a strong reduction in the endosomal staining pattern of RME-8. Thus, in
addition to interacting with PI(3)P beads in vitro, RME-8 associates with PI(3)P
containing vesicles in cellula.
RME-8 possesses a DnaJ domain in the C-terminal half of the protein that is
responsible for interacting with Hsc70 [62, 89]. The C-terminal region also mediates the
reported interaction between RME-8 and sorting nexin 1[83]. On the other hand, the Nterminal region has been shown to mediate the membrane localization of RME-8 [90].
Likewise, PIP pull down assays were performed with RME-8 deletion constructs to
determine which RME-8 region was responsible for the observed PI(3)P and PI(3,5)P2
binding. The results showed that full length RME-8 and a variant encompassing all but
the last 425 amino acids were able to associate with PI(3)P and PI(3,5)P2. In contrast,
deletion of the first 453 amino acids completely abolished binding to PI(3)P and
PI(3,5)P2 (Fig. 2.4). Taken together, our results strongly suggest that RME-8 is a novel
PI(3)P binding protein both in vitro and in cells.
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Figure 2.4. Deletion of the N terminal region of RME-8 abolishes RME-8-PI(3)P
association. Hek 293 cellular lysates expressing GFP-RME-8 variants were subjected to
a PI(3)P pulldown (A) or a PI(3,5)P2 pulldown (B) as described in Materials and Methods
and analyzed by immunoblotting using a GFP antibody. Immunoblots representative of
three independent trials are shown. GFP-RME-8 variants included full length GFP-RME8, GFP-RME-8·N453 and GFP-RME-8·C425.
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2.3.3. MTMR2 attenuates the association of RME-8 with the early endosome

We have recently discovered that MTMR2 is highly phosphorylated on Ser58
which sequesters MTMR2 in the cytoplasm and limits access to its lipid substrates.
Conversely, a phosphorylation deficient mutant, MTMR2 S58A, is capable of localizing
to endosomal vesicles and depleting PI(3)P.

Therefore, to address whether the PI(3)P

binding ability of RME-8 could be affected by MTMR2, RME-8 was co-expressed with
MTMR2 S58A and the integrity of the RME-8 endosomal pattern was analyzed by
immunofluorescent microscopy. When overexpressed alone, GFP-RME-8 and MTMR2
S58A both exhibited the characteristic punctate endosomal localization pattern (Fig.
2.5A, B, left panels). Strikingly, co-expression of MTMR2 S58A resulted in significant
loss of the RME-8 endosomal localization pattern (Fig. 2.5A, upper right panel), as did
treatment with wortmannin (Fig. 2.5B, right panel).

Furthermore, expression of a

catalytically inactive variant (MTMR2 S58A.C417S) failed to disrupt the endosomal
localization pattern of RME-8 (Fig. 2.5A, lower right panel), suggesting that the
association of RME-8 with PI(3)P rich vesicles can be disrupted by the phosphatase
activity of MTMR2.
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FLAG-MTMR2 S58A

GFP-RME-8

GFP-RME-8
+ MTMR2
S58A

GFP-RME-8
+ MTMR2
S58A.
C417S

B

- Wortmananin

+ Wortmannin

GFPRME-8

Figure 2.5. MTMR2 S58A alters the endosomal localization pattern of RME-8. (A)
HeLa cells were transiently transfected with FLAG-MTMR2 S58A or FLAG-MTMR2
S58A.C417S and GFP-RME-8 and analyzed by immunofluorescence microscopy.
Alteration of the localization pattern of GFP-RME-8 is observed when co-expressed with
FLAG-MTMR2 S58A (A, upper panel) or when cells are treated with wortmannin (B).
Images were collected using 63× objectives. The scale bar represents 10 µm.

46

RME-8 has been previously shown to regulate the endosomal sorting of a variety
of cargo at the early to late endosome interface, including the epidermal growth factor
receptor (EGFR) [83, 90, 95, 97]. Similarly, in HeLa cells that were stimulated with
EGF, GFP-RME-8 displayed significant co-localization with EGFR (Fig. 2.6A).

To

ascertain the compartment where RME-8 and EGFR co-localize we utilized triple
staining immunofluorescence with the early endosome marker Rab5 (Fig. 2.6B) and the
late endosome/lysosomal marker LAMP1 (Fig. 2.6C). Although EGFR was found to
partially co-localize with both of these markers, vesicles containing EGFR and RME-8
only co-stained with Rab5 and not LAMP1 suggesting that RME-8 co-localizes with
EGFR on early endosomes. Meanwhile, expression of MTMR2 S58A disrupted the
ability of RME-8 to co-localize with the EGFR (Fig. 2.6D). Again, this disruption
required the phosphatase activity of MTMR2 as RME-8 was capable of co-localizing to
EGFR positive vesicles in the presence of the catalytically inactive mutant of MTMR2
(Fig. 2.6E). Collectively, these results demonstrate that MTMR2 regulates the PI(3)P
dependent targeting of RME-8 to EGFR-positive early endosomes.
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Figure 2.6. GFP-RME-8 co-localization with EGFR on early endosomes is disrupted
by MTMR2 S58A. HeLa cells were transiently transfected with GFP-RME-8, serum
starved for two hours and then stimulated with EGF (20 ng/ml) for 15 min. Cells
expressing GFP-RME-8 alone (A–C) or co-expressing MTMR2 S58A (D), or MTMR2
S58A.C417S (E) were analyzed by immunofluorescence microscopy. Cells were probed
for endogenous EGFR and GFP-RME-8 co-localization with the early endosome marker
Rab5 (B) or late endosome/lysosomal marker LAMP1 (C). Arrowheads represent
vesicles displaying significant co-localization. Images were collected using 63X
objectives. The scale bar represents 15 µm.
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In conclusion, our results have elucidated a novel mechanism for regulating
RME-8 endosomal targeting.

As RME-8 in a variety of organisms has clearly

demonstrated to be a critical regulator of endosomal processing, determining the temporal
and spatial details of how PI(3)P regulates the docking of RME-8 to endosomal vesicles
will deepen our understanding of the specific role of RME-8 in vesicular trafficking.
Seeing that RME-8 is expressed in a variety of mammalian tissues [95], it will also be
interesting to investigate if other MTMRs can regulate RME-8 to the same extent as
MTMR2. Finally, as CMT4B1 is caused by loss of a functional MTMR2, our findings
open the door to examining if RME-8 is overactive and contributes to the demyelination
phenotypes in CMT 4B1.
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CHAPTER 3
RECEPTOR MEDIATED EDOCYTOSIS 8 UTILIZES AN N-TERMINAL
PHOSPHOINOSITIDE-BINDING MOTIF TO REGULATE ENDOSOMAL
CLATHRIN DYNAMICS
3.1. Introduction

Endocytosis is a highly regulated and diverse process of plasma membrane and
extracellular matrix internalization that participates in a variety of cellular processes [5456]. Recent work in the field has revealed that endocytic vesicles are heterogeneous
macromolecular complexes, making it critical to further identify and fully characterize
factors that associate and regulate endocytic events such as endosomal signaling,
endosomal maturation, cargo sorting, cargo recycling, and cargo degradation. Receptormediated endocytosis 8 (RME-8) was first discovered utilizing genetic screens in
Caenorhabditis elegans , where rme-8 mutants exhibited defects in receptor-mediated
yolk endocytosis in the oocyte and fluid phase endocytosis in the coelomocyte [89].
Likewise, studies of rme-8 mutants in Drosophila displayed blockage in the
internalization of the Bride of Sevenless receptor causing the formation of the rough eye
phenotype [62]. RME-8 has not only been shown to be highly conserved in the animal
kingdom [90, 95], but it is also present in plants, where studies in Arabidopsis thaliana
have demonstrated that RME-8 mutants exhibit gravitropism defects and associate with
endosomal structures [98]. Finally, a recent study has determined that a gain of function
mutation in RME-8 correlates with Parkinson disease [99], highlighting the importance of
studying RME-8 biology in more detail. RME-8 is a large protein composed of more than
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2000 amino acids. It contains four IWN repeats of unknown function and a DnaJ binding
domain located between the second and the third IWN repeat that has been shown to
associate with heat shock protein Hsc70 in a variety of species[62, 86, 90, 95]. DnaJ
protein family members act as coupling factors to stimulate ATP hydrolysis by its partner
heat shock protein and thus they function as co-chaperones [100]. The pleiotropic Hsc70
has a well established role in the disassembly of clathrin [101]. Clathrin is crucial for
vesicle formation at the plasma membrane during clathrin mediated endocytosis and for
protein sorting from early endosomes [102]. In the case of endocytosis, the DnaJ domain
protein auxillin recruits Hsc70 to release clathrin coats from clathrincoated vesicles by
binding to the terminal domain of clathrin heavy chain [88, 101, 103]. Clathrin-coated
vesicles are also fea tured on early endosomes and are the target of the RME-8/ Hsc70
complex where they are employed to sort cargo from early endosomes to the trans-Golgi
network (TGN) during retrograde transport [62, 86, 104, 105]. In addition to binding
Hsc70, RME-8 has also been shown to associate and co-localize with the endosome
membrane remodeling component SNX1 [83, 86]. SNX1 when complexed with SNX2
recruits the Vps26-Vps29-Vps35 retromer trimer to form the heteropentameric coat, also
known as retromer [81]. SNX1 contains a phox (PX) domain that binds specifically to
phosphatidylinositol 3-phosphate (PI(3)P). Subsequently, the Vps26-Vps29-Vps35 trimer
is recruited and recognizes the transmembrane cargo to be sorted from early endosomes
to the trans-Golgi network during retrograde transport [81, 106, 107]. In mammals, a well
characterized transmembrane protein that is sorted by a retromer is the cationindependent mannose 6-phosphate receptor (CI-MPR) [81, 106]. Generally, newly
synthesized acid hydrolase precursor proteins are recognized by the CI-MPRs at the TGN
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membranes and are later sorted at early endosomes. After acid hydrolases reach the
lumen of early endosomes, they dissociate from the receptor due to the acidic
environment. They are then directed to lysosomes to degrade biological material, whereas
the acid hydrolase receptors escape the early-to-late endosomal degradation pathway and
are transported to the TGN through the retrograde transport pathway [71, 79, 81]. A
prominent mechanism during endosomal processing events is the recruitment of target
effector proteins through association with PI(3)P on the surface of early endosomes. We
have recently discovered that RME-8 associates with PI(3)P containing early endosomes
in a myotubularin-related-2-dependent manner [108]. Here, we have now identified
critical residues mediating PI(3)P binding within the N terminus of RME-8. We have
characterized this PI(3)P binding region in terms of its biochemical properties and
examined its requirement for RME-8 activities at the early endosome.

3.2. Materials and Methods

3.2.1. Plasmid Constructs

The plasmids encoding GFP-RME-8 were a kind gift from Drs. Fujibayashi and
Sekiguchi from Osaka University, Osaka, Japan [90]. Site-directed mutagenesis was
performed to generate RME-8 point mutants. The forward and reverse primers for the
GFP-RME8 K8A mutant are 5’-TAATTAGGGAAAATGCGGATCTGGCATGTT-3’
and 5’-AACATGCCAGATCCGCATTTTCCCTAATTA-3’. The forward and reverse
primers

for

generation

of

the

GFP-RME-8

TTCTACACAACAGCACATTCATGGAG-3’
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K17A
and

mutant

are

5’5’-

CTCCATGAATGTGCTGTTGTGTAGAA-3’. To generate the GFP-RME-8 W20A
mutant,

the

forward

primer

used

was

5’-

CAACAAAACATTCAGCGAGGGGGAAGTATA-3’, whereas the reverse primer was
5’-TATACTTCCCCCTCGCTGAATGTTTTGTTG-3’. The forward primer for GFPRME-8 Y24A was 5’- CATGGAGGGGGAAGGCTAAGCGTGTCTTTT-3’ , and the
reverse was 5’ -AAAAGACACGCTTAGCCTTCCCCCTCCATG-3’. The forward
primer

for

the

generation

of

GGGAAGTATGCGCGTGTCTTTTC-3’,

GFP-RME-8
and

the

K25A
reverse

was

5’-

was

5’-

AAGACACGCGCATACTTCCCCCT-3’. The forward primer for the generation of
GFP-RME-8 R26A was 5’-GGGAAGTATAAGGCTGTCTTTTCAGTT-3’, and the
reverse was 5’-AACTGAAAAGACAGCCTTATACTTCCC-3’. All the constructs
generated were verified by automated DNA sequencing (ACGT Corp). FLAG-Hsc70 and
mRFP-SNX1 constructs were the kind gifts from Dr. Frank R. Sharp (University of
California at Davis) and Dr. Peter J. Cullen (University of Bristol), respectively. Site
directed mutagenesis was performed to generate the mRFPSNX1 K214A point mutant.
The

forward

and

reverse

primers

for

CCGCCCCCGGAGGCAAGCCTCATAGGGA-3’

mRFP-SNX1

K214A
and

are

5’5’-

TCCCTATGAGGCTTGCCTCCGGGGGCGG-3’.

3.2.2. Bioinformatics Analysis

RME-8 sequences were obtained by NCBI (www.ncbi.nlm.nih.gov), and
orthologue sequences were aligned utilizing ClustalW multiple sequence alignment
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program [109]. The three-dimensional structure prediction model of RME-8 was obtained
by submitting the sequence of the first 100 amino acids of RME-8 to Protein
Homology/AnalogY Recognition Engine Version 2.0 (Phyre2) [110, 111]. The predicted
three-dimensional structure of RME-8 generated from Phyre2 was superimposed onto the
structure of the FERM domain of talin (Protein Data Bank code d1mixa2) using the
Swiss-PDB Viewer (Deep View) [112, 113].

3.2.3. Cell Culture, Transfection, and Cell Lysis

HeLa (ATCC) and HEK293 (ATCC) cells were maintained in DMEM/F-12 with
10% FBS, 2 mM L-glutamine and supplemented with 1% penicillin/streptomycin
antibiotics at 37 °C and 5% CO2. Cells were seeded 24 h before transfection. Following
transient transfection with 5 µg of DNA using FuGENE HD (Roche Applied Science)
using the manufacturer’s protocol, cells were lysed with lysis buffer (50mM Tris-HCl,
pH 7.4, 1% Nonidet P-40, 76 mM NaCl, 2 mM EGTA, 10% glycerol) supplemented with
protease inhibitors 1 mM phenylmethylsulfonyl fluoride and 1 mM aprotinin.
Knockdown of endogenous RME-8 and SNX1 protein expression was performed using
ON-TARGET siRNA SMARTpools (Dharmacon). HeLa cells were transfected with
RME-8 and SNX1 siRNAs to a final concentration of 25 nM using DharmaFECT 1
transfection reagent following the manufacturer’s protocols. Cells were then incubated
with antibiotic- free media for 48 h before analysis.
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3.2.4. Phosphatidylinositol Pulldown

HEK293 were transiently transfected with GFP-RME-8 variants and lysed as
described above. Cellular lysates were incubated overnight at 4 °C with various
phosphatidylinositol (PI) phosphates conjugated to resin (Echelon Biosciences),
including control PI beads, PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, and
PI(3,4,5)P3. Following three washing steps with washing/binding buffer (10 mM HEPES,
pH 7.4, 150 mM NaCl, 0.25% Nonidet P-40), protein samples were subjected to SDSPAGE analysis. Afterward, the samples were transferred onto a PVDF membrane and
incubated with goat anti-GFP (Rockland) and anti-goat HRP (Rockland) antibodies at
room temperature for 1 h. Proteins were visualized using SuperSignal West Femto
Reagent (Thermo Scientific).

3.2.5. Liposomal Floatation Assay

40 and 30% Opti-Prep density gradient medium (Sigma) was prepared in
washing/binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.25% Nonidet P-40).
HEK293 cells were lysed with 50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 76 mM
NaCl, 2 mM EGTA, 10% glycerol lysis buffer. Cellular lysates were incubated with
control PI or PI(3)P-polymerized liposomes (PolyPIPosomes, Echelon Biosciences) for 2
h at room temperature. Following incubation, 60% Opti-Prep density gradient medium
(Sigma) was added to obtain a final 40% Opti-Prep density gradient. The
protein/liposome mixtures were added to thick-walled polycarbonate tubes (Beckman
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Coulter). 30% Opti-Prep density gradient medium was then overlaid on top of the 40%
layer. Finally, wash/binding buffer was added as the top layer. Samples were spun in an
ultracentrifuge at 50,000 rpm for 3 h at room temperature. After centrifugation, SDSPAGE loading dye was added, and protein samples were analyzed by immunoblotting.

3.2.6. Co-immunoprecipitation

For the RME-8/Hsc70 co-immunoprecipitation, we co-transfected HEK293 cells
with GFPRME-8 variants and FLAG-Hsc70 for 24 h, and cells were lysed as described
above. Cellular lysates were incubated with FLAG protein A-agarose beads (Sigma)
overnight at 4 °C. Immunoprecipitates were washed three times with 50mM Tris-HCl,
pH 7.4, 0.1% Triton X-100, 150 mM NaCl, 0.1% SDS and analyzed by immunoblotting
using anti-FLAG (Sigma), goat anti-GFP (Rockland), rabbit anti-actin (Sigma), and
secondary antibodies anti-mouse HRP (Promega), anti-goat HRP (Rockland), and antirabbit HRP (Vector Laboratories). For RME-8/SNX1 coimmunoprecipitations, we
transfected cells with GFP-RME-8 variants for 24 h. We pre-bound the protein A-agarose
beads with 1 μg of goat anti-GFP antibody for 45 min at room temperature. Following
washing steps, we incubated cellular lysates with the conjugated beads overnight at 4 °C.
Samples were washed three times as described above and analyzed by immunoblotting.
Anti-SNX1 (BD Transduction Laboratories) was used to detect endogenous SNX1.
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3.2.7. Immunofluorescence and Image Analysis

HeLa cells were seeded on four-chamber slides (BD Biosciences) 24 h prior to
transient transfection with 0.5 μg of DNA using FuGENE HD. Slides were fixed for 15
min with 3.7% paraformaldehyde at room temperature. Cells were then permeabilized
with 0.15% Triton X-100 for 2 min and blocked with 5% BSA for 1 h at room
temperature. Primary antibodies, including mouse anti EEA-1 (BD Biosciences), rabbit
anti-EEA-1 (Sigma), goat anticlathrin (Santa Cruz Biotechnology), mouse anti-CI-MPR
(Abcam), and rabbit anti-SNX1 were incubated for 1 h. Rabbit anti-RME-8 antibody was
a kind gift from Dr. Peter McPherson (McGill University, Canada). Following washes,
cells were incubated with the appropriate Alexa secondary antibodies (Life Technologies,
Inc.) for 1 h at room temperature. Cells were washed, stained with Hoechst stain (0.5
mg/ml) (Invitrogen) for 2 min, and mounted on the slide. Confocal fluorescence
microscopy was utilized to capture the images using a x 40 oil and a x 60 water objective.
To determine the extent of co-localization between EEA1-positive endosomes and RME8, Pearson’s correlation coefficients were measured. Pearson’s correlation coefficient
values were calculated using ImageJ software via JACoP plugin (National Institutes of
Health) [114]. Data in the bar graphs represent the average of 30 randomly selected cells
examined for co-localization.
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3.3. Result and Discussion

3.3.1. Identification of the RME-8 PI(3)P- Binding Motif

Earlier studies have shown that RME-8 associates with early endosomes [83, 90,
95], and recently our laboratory has discovered RME-8 to be a novel PI(3)P-binding
protein that is regulated by the PI(3)P phosphatase MTMR2 [108]. Because RME-8 does
not contain a classical PI(3)P binding domain (e.g. FYVE domain, PX domain) we
sought to localize the PI(3)P-binding motif in RME-8. To guide this process, the primary
sequence of RME-8 was analyzed by the Phyre2 protein folding prediction program [110,
111]. The result of this analysis was a high confidence score predicting the presence of a
pleckstrin homology (PH)-like binding fold present in the first 100 amino acids of RME8. Along with predicting homology with PH domains from a variety of proteins, the
highest homology was with the PH domain of the PI(4,5)P2-binding protein Talin) (94%
confidence) (Fig. 3.1, A and B) [115, 116]. Further homology modeling using the SwissPDB Viewer and the three-dimensional structure of the PH domain of Talin (Protein Data
Bank code d1mixa2) was performed (Fig. 3.1A). The resulting structural model revealed
strong alignment with a portion of the PH fold of Talin, complementing the Phyre2
prediction program result. Generally, most PH domain binding interfaces reside on loop
structures that link β-strands [50]. Examining these regions on the RME-8/Talin model
revealed residues in the extreme N terminus of RME-8 predicted to reside on such loop
structures (Fig. 3.1A). Moreover, when examining this N-terminal region in RME-8, it
was determined that many of these residues are highly conserved among orthologues
(Fig. 4.1C), leading us to hypothesize their involvement in PI(3)P binding (Fig. 3.1, C
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and D). This region contains many positively charged residues and several bulky
hydrophobic residues conserved among orthologues. Such residues have been shown to
be functionally critical in PH domains [50] as well as other PI(3)P binding domains such
as PX and FYVE domains [117, 118].
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Figure 3.1. RME-8 contains a putative phosphoinositide-binding motif. A, structural
homology model depicting RME-8 (red) aligned with the solved structure of Talin’s
FERM third subdomain (blue) (27). The first 100 amino acids of RME-8 sequence were
first submitted to the Phyre2 server for homology detection followed by Swiss-PDB
Viewer to produce the structural model (see “Experimental Procedures”). Solventexposed amino acids of interest (Lys17, Trp20, Tyr24, and Arg26) in RME-8 that
potentially represent a phosphoinositide-binding interface are shown in green. B,
alignment of RME-8 and FERM’s PH-like subdomain (d1mixa2). Sequences are aligned
based on the secondary structure homology predicted by the Phyre2 server. Blue arrows
represent β-strands, and the amino acids in bold represent amino acid identity. C, multiple
sequence alignment of the N-terminal region of RME-8 orthologues. The RefSeq
accession numbers used were the following: Homo sapiens, AAV41096.1; Mus
musculus, NP_001156498.1; Drosophila melanogaster, NP_610467.1; C. elegans,
AF372457_1; A. thaliana, AEC07904.1; Desmodus rotundus, JAA50105.1; Leishmania
donovani, CBZ36243.1; Ixodes ricinus, JAB76328.1; Capsaspora owczarzaki,
EFW44108.1; Apis mellifera, XP_394533.4; and Chlamydomonas reinhardtii,
EDP05338.1. Based on the ClustalW alignment, the putative signature phosphoinositidebinding motif of RME-8 to is KXSW(K/R)G(K/R)YXR. D, schematic presentation of
thehumanRME-8 protein with itsIWNrepeats (gray boxes) and its DnaJ domain (black
box) shown. The proposed RME-8 PI(3)P-binding motif targeted for subsequent
mutagenesis studies is highlighted.
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PH domains have been shown to bind to a variety of phosphoinositide isoforms,
in particular isoforms with vicinal phosphates such as PI(3,4)P2 and PI(4,5)P2 [50].
Therefore, it was important to examine the phosphoinositide specificity of RME-8. To
accomplish this, HEK293 cells expressing wild type RME-8 were lysed and incubated
with each of the seven phosphatidylinositol phosphates (PIP) conjugated to resin, and
binding specificity was assessed via immunoblotting (Fig. 3.2). Consistent with earlier
studies [108], RME-8 associates with PI(3)P and PI(3,5)P2 while failing to associate with
the products of MTMR2, PI or PI(5)P. Furthermore, RME-8 shows no appreciable
association with PI(4)P, PI(3,4)P2, or PI(4,5)P2. Interestingly, RME-8 did associate with
PI(3,4,5)P3 to a similar extent as PI(3)P and PI(3,5)P2. Although the finding that RME-8
can associate with resin functionalized with PI(3,5)P2 and PI(3,4,5)P3 is potentially
biologically relevant (see discussion below), the focus of this study was regulation of
RME-8 at early endosomes. Thus, subsequent analysis focused on delineating residues
important for association with PI(3)P.
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Figure 3.2. RME-8 binds PI(3)P, PI(3,5)P2, and PI(3,4,5)P3 in vitro. A, HEK293
cells were transiently transfected with wild type RME-8 for 24 h. Cells were then lysed as
described under “Experimental Procedures” and subjected to pulldowns with the
following lipid groups: PI, PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, and
PI(3,4,5)P3. Following elution, immunoblots (IB) were probed with anti-GFP antibody to
detect GFP-RME-8. Whole cell lysates were analyzed by GFP and actin immunoblotting
to confirm equal GFP RME-8 and total protein levels. B, lipid pulldown assay was
quantified by densitometry using ImageJ software and normalized to actin levels. Means
±S.D. of three independent experiments are shown (n = 3). p values were calculated by
the Student’s t test comparing each sample to GFP-RME-8. **, p <0.01; *** p <0.001.
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As noted above, the predicted PH-like fold region in the N terminus of RME-8
contains several highly conserved residues with the potential to mediate PI(3)P binding.
Therefore, we examined the effect of substituting a variety of positively charged and
bulky hydrophobic residues within this region for PI(3)P binding using the PIP pulldown
assay (Fig. 3.3). Lysates generated from HEK293 cells expressing RME-8 variants were
incubated with resin containing PI or PI(3)P. Following washing and SDS-PAGE
separation, the PI(3)P binding activity of RME-8 variants was determined by
immunoblotting. As expected, wild type RME-8 associates with PI(3)P. Moreover, RME8 K8A and RME-8 K25A variants also display no significant difference in their ability to
interact with PI(3)P. In contrast, the RME-8 variants K17A, W20A, Y24A, and R26A
show markedly reduced capacity to associate with PI(3)P in this in vitro pulldown assay
(Fig. 3.3, A and B ). These results demonstrate that Lys17 , Trp20 , Tyr24 , and Arg26
represent possible determinants for an N-terminal PI(3)P-binding motif within RME-8.
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Figure 3.3. Lys17, Trp20, Tyr24, and Arg26 are involved in RME-8 PI(3)P binding in
vitro. Continued
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Figure 3.3. Lys17, Trp20, Tyr24, and Arg26 are involved in RME-8 PI(3)P binding in
vitro. Continued
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Figure 3.3. Lys17, Trp20, Tyr24, and Arg26 are involved in RME-8 PI(3)P binding in
vitro. A, HEK293 cells were transiently transfected with wild type RME-8, RME-8 K8A,
RME-8 K17A, RME-8 W20A, RME-8 Y24A, RME-8 K25A, and RME-8 R26A
constructs for 24 h. Cells were lysed as described under “Experimental Procedures” and
subjected to PI and PI(3)P lipid pulldowns. Subsequent immunoblots were probed with
anti GFP to detect GFP-RME-8 variants. Whole cell lysates were analyzed by GFP
immunoblotting (IB) to confirm equal GFP-RME-8 expression levels. A representative
blot from three independent experiments is shown (n=3). B, lipid pulldown assays
quantified by densitometry using ImageJ software and normalized to actin levels. Means
± S.D. of three independent trials are shown. p values were calculated by the Student’s t
test and compared with wild type RME-8, **, p<0.01; ***, p<0.001. C, HEK293 cells
expressing wild type RME-8 (wt) and RME-8W20Awere subjected to liposomal flotation
assays. Lysates incubated with PI liposomes and PI(3)P liposomes were separated using
an Opti-Prep gradient and ultracentrifugation. Gradient fractions were then analyzed by
immunoblot analysis. Representative blots from three independent experiments are
shown (n=3). D, liposome flotation assay quantified by densitometry using ImageJ
software. Means ± S.D. of three independent trials are shown. p values were calculated
by the Student’s t test and compared with wild type RME-8. ***, p < 0.001.
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To complement the bead-based pulldown assay, we also examined the ability of
wild type RME-8 and a representative binding mutant RME-8 W20A to associate with
liposomes containing PI(3)P using liposome flotation assays [119]. HEK293 cells
expressing wild type RME-8 or RME-8 W20A were incubated with PI or PI(3)P
containing liposomes followed by the addition of an Opti-Prep density gradient solution.
Samples were subjected to ultracentrifugation upon which the PI(3)P liposomes (along
with any bound RME-8) migrate to the top portion of the gradient. Gradients were then
fractionated and analyzed by immunoblotting (Fig. 3.3, C and D ). We reproducibly
observed a significant portion of wild type RME-8 fractionate with the top PI(3)P
liposome containing fraction but not with liposomes loaded with PI. Moreover, RME-8
W20A was defective at fractionating with the PI(3)P liposomes suggesting that RME-8
can associate with PI(3)P liposomes and that Trp20 is required for PI(3P) binding
activity.

3.3.2. PI(3)P-binding Mutants Attenuate RME-8 Association with PI(3)P-rich early endosomes

It has been demonstrated that RME-8 displays a punctate localization pattern due
to its association with early endosomal structures [68, 83, 89, 95, 108] that can be
disrupted by the PI(3)-kinase inhibitor wortmannin and expression of the PI(3)P
phosphatase MTMR2 [108]. Therefore, to complement the above biochemical assays, we
screened the various RME-8 mutants for subcellular localization changes from punctate
to a diffused cytoplasmic pattern. As shown in Fig. 3.4, wild type RME-8, RME-8 K8A,
and RME-8 K25A variants display a punctate pattern consistent with functional
endosomal localization. In contrast RME-8 K17A, RME-8 W20A, RME-8 Y24A, and
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RME-8 R26A significantly lost the RME-8 punctate pattern, instead displaying largely
diffuse cytoplasmic localization.
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Figure 3. 4. RME-8 K17A, W20A, Y24A, and R26A alter the subcellular localization
of RME-8. HeLa cells were transiently transfected with wild type RME-8, RME-8 K8A,
RME-8 K17A, RME-8 W20A, RME-8 Y24A, RME-8 K25A, and RME-8 R26A and
analyzed by confocal microscopy as described under “Experimental Procedures.” Images
were collected using a X40 objective. Scale bars, 15 µm.
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To test whether these residues would be involved in dictating RME-8 PI(3)Pdependent early endosomal localization in cellula , we utilized immunofluorescence
microscopy to examine co-localization of RME-8 variants with endogenous EEA-1,
which is a well characterized PI(3)P early endosome marker (Fig. 3.5) [118, 120, 121].
Consistent with our pulldown experiments, RME-8 K8A and RME-8 K25A co-localize
with EEA1 to a similar extent as wild type RME-8 (Fig. 3.4, A and C ), indicating that
these Lys residues likely are not critical for PI(3)P binding. On the contrary, RME-8
K17A, RME-8 W20A, RME-8 Y24A, and RME-8 R26A failed to associate with PI(3)Prich EEA1 early endosomes as indicated by loss of co-localization with EEA-1 along
with diffuse cytoplasmic localization (Fig. 3.5, B and C ).
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Figure 3.5. RME-8 early endosome localization requires Lys17, Trp20, Tyr24, and
Arg26. Continued
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Figure 3.5. RME-8 early endosome localization requires Lys17, Trp20, Tyr24,
and Arg26. Continued
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Figure 3.5. RME-8 early endosome localization requires Lys17, Trp20, Tyr24, and
Arg26. A and B, HeLa cells were transfected with wild type RME-8, RME-8 K8A, RME8 K17A, RME-8 W20A, RME-8 Y24A, RME-8 K25A, and RME-8 R26A (green) for 24
h and stained for EEA1 (red). Co-localization was analyzed by confocal microscopy. A,
wild type RME-8, RME-8 K8A, and RME-8 K25A co-localize with EEA-1-positive
early endosomes. B, absence of co-localization between RME-8 K17A, RME-8 W20A,
RME-8 Y24A, and RME-8 R26A with EEA1 at early endosomes. Solid white arrows
show regions of co-localization. Expanded boxes represent regions of interest. Images
were collected using a X40 objective. Scale bars, µ15m. C, Pearson’s correlation
coefficient (PC) was utilized to quantify the extent of co-localization between RME-8
and EEA-1-positive endosomes. Means ±S.D. of three independent experiments (n = 30
cells) are shown. p values were calculated by the Student’s t test and compared with wild
type RME-8, *, p < 0.1; **, p < 0.01; ***, p < 0.001.
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Taken together, our data indicate that RME-8 binds PI(3)P biochemically in vitro
and on early endosomes in cellula through a novel N-terminal binding motif that is
predicted to reside within a PH-like folded domain. Moreover, residues Lys17 , Trp20 ,
Tyr24 , and Arg26 were identified as key determinants for competent PI(3)P association.
Akin to other PI(3)P-binding proteins, RME-8 utilizes a combination of hydrophobic and
positive charge functional groups for association with PI(3)P. In particular, the PX
domain also possesses invariant Lys and Tyr residues to drive PI(3)P binding [122, 123].
It is interesting to note that analogous to RME-8, PX-containing proteins have also been
shown to associate with PI(3,5)P2 [79, 122-125]. This is in contrast to the FYVE domain,
whose structurally distinct zinc coordination and small positively charged pocket is
postulated to be too small to accommodate PI(3,5)P2 [126]. Another distinguishing
feature of RME-8’s PIP specificity is the interaction with PI(3,4,5)P3

in the PIP

pulldown assay (Fig. 3.2). Further structure-function analysis will be required to
experimentally determine whether the N-terminal region of RME-8 truly adopts a PHlike fold and to examine whether RME-8’s association with PI(3,5)P2 and PI(3,4,5)P3 is
biologically relevant. However, it is interesting to note that in addition to early
endosomes, RME-8 has been reported to localize to late endosomes and recycling
endosomes, which are known to contain PI(3,5)P2 and PI(3,4,5)P3 , respectively [89, 95,
127]. Thus, it will be interesting to assess whether these PIP isoforms localized on
distinct endosome subtypes regulate subcellular localization of RME-8.
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3.3.3. RME-8 does not require its PI(3)P-binding for association with Hsc70

Hsc70 binds DnaJ domain-containing cofactor proteins and is involved in ATPdependent clathrin dissociation from clathrin-coated vesicles [128]. Studies in
Drosophila, C. elegans, and humans have shown that RME-8 binds the ATPase domain
of Hsc70 through its DnaJ domain [62, 83, 86, 95, 128]. Intriguingly, RME-8 is the only
known PI(3)P-binding protein that recruits Hsc70 to early endosomes via its DnaJ
domain. Because the mechanism by which these two molecules regulate clathrin is not
well characterized, it was of interest to explore whether the RME-8/Hsc70 interaction
was maintained in RME-8 PI(3)P-binding mutants. Co-immunoprecipitation experiments
were conducted using HEK293 cells expressing GFP-RME-8 variants and FLAG-Hsc70
followed by GFP immunoprecipitation and immunoblot analysis (Fig. 3.6 A). All of the
RME-8-binding mutants that were found to disrupt PI(3)P association were able to coimmunoprecipitate Hsc70 to a similar extent when compared with wild type RME-8. The
GFPRME-8 ΔC1165 truncation mutant, which is devoid of its DnaJ domain (6), was also
analyzed as a negative control, and as expected it was largely defective at coimmunoprecipitating Hsc70. The data strongly indicate that the RME-8/Hsc70 interaction
is not perturbed by the ability of RME-8 to bind PI(3)P. The notion that the PI(3)P
binding activity of RME-8 is segmented from its protein-protein binding activity was
confirmed using another interacting partner, SNX1. As shown in Fig. 3.6 B, we observed
RME-8 W20A to co-immunoprecipitate endogenous SNX1 to a similar extent as wild
type RME-8. In addition to indicating that mutating residues in the N-terminal PI(3)P
binding region does not disrupt the functional fold of other RME-8 domains, this finding
also signifies that RME-8 may potentially associate with Hsc70 or SNX1 away from
79

endosomal structures.
It remains unclear how Hsc70 is distributed between auxillin and RME-8 during
endocytosis and endosome maturation, respectively. One possibility is that due to the
relative high concentration of Hsc70 in the cell, there are sufficient amounts of Hsc70
protein to partition within the two complex pools independently. Alternatively, PI(3)P
levels may play a role in signaling the cell toward forming the RME-8/Hsc70 complex
for sorting processing. In either case, our results signify that the endosomal clathrin
uncoating activity of Hsc70 may potentially be indirectly regulated by PI(3)P levels via
its interaction with RME-8.
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Figure 3.6. Wild type RME-8 and PI(3)P-binding mutants associate with Hsc70 and
SNX1. A, HEK293 cells were transiently co-transfected with GFP-RME-8 and FLAGHsc70 constructs for 24 h. Cellular lysates were then incubated with anti-FLAG proteinA-agarose beads. Following extensive washing steps, RME-8 bound to FLAG-Hsc70 was
analyzed via immunoblotting (IB) using an anti-GFP antibody. IP, immunoprecipitation.
Actin served as a cell number control. B, HEK293 cells were transiently transfected with
wild type GFP-RME-8 or GFP-RME-8 W20A for 24 h. Lysates were subjected to antiGFP immunoprecipitation and probed for endogenous SNX1 using immunoblot analysis.
Actin served as a cell number control (Neg. Cont). A representative blot from three
independent experiments is shown (n = 3).
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3.3.4. Functional PI(3)P binding is required for RME-8 mediated early endosomal clathrin
regulation

One of the hallmarks of membrane trafficking is cargo recognition and sorting
from one cellular compartment to the other. Following cargo concentration into patches,
the membrane undergoes deformation into smaller coated vesicles containing the cargo of
interest [87]. One of these coats is clathrin, which has been shown to regulate the
trafficking of retrograde transport receptors at early endosomes [83, 84, 86, 87] in
addition to its role in the endocytosis of receptors at the plasma membrane. Recent
studies have revealed that the retromer complex controls endosomal clathrin levels
through its incorporation of the RME-8/Hsc70 tandem [83, 86]. Interestingly, the loss of
either RME-8 or Hsc70 results in early endosomal clathrin accumulation [62, 95]. Having
established that the RME-8/Hsc70 association is preserved in RME-8 PI(3)P-binding
mutants, we hypothesized that early endosomal clathrin levels would be perturbed in
RME-8 PI(3)P-binding mutants due to the inability of Hsc70 to access the endosomal
clathrin structures. To examine this hypothesis, HeLa cells were transiently transfected
with wild type or the RME-8 W20A variant. We chose the RME-8 W20A variant as the
representative binding mutant for this and all subsequent experiments due to its extensive
conservation among RME-8 orthologues and based on the structural model that predicts
Trp20 of residing on an exposed loop that could potentially serve as a strong binding
interface (Fig. 3.1). Following fixation, cells were triple-labeled for endogenous EEA-1
(red), endogenous clathrin heavy chain (green), and GFP-RME-8 (blue) (Fig. 3.7). The
extent of co-localization between clathrin (green) and EEA-1 (red) was calculated as a
measure of co-localization between the two channels (Fig. 3.7 E). Of interest were RME8 decorated early endosomes that were positive for PI(3)P (EEA-1). Analysis of these
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structures revealed a clear pattern where vesicles that were positive for RME-8 and
PI(3)P (EEA-1) were largely devoid of clathrin (Fig. 3.7A). Interestingly, early
endosomes that were lacking RME-8 (shown by arrowheads, Fig. 3.7A ) displayed strong
co-localization between PI(3)P (EEA-1) and clathrin. These results emphasize the
function that RME-8 plays at the early endosomes and its involvement in clathrin
regulation. Conversely, HeLa cells transfected with siRNA targeting RME-8 expression
resulted in an endosomal clathrin phenotype opposite of overexpressing wild type RME-8
with increased co-localization between clathrin and the PI(3)P marker EEA-1 (Fig.
3.7D). We observed an analogous phenotype by knocking down the protein expression of
SNX1 by siRNA (Fig. 3.7E). Interestingly, similar to the siRNA-treated samples, cells
expressing RME-8 W20A displayed a statistically significant increase in co-localization
of early endosomal clathrin on EEA-1-positive early endosomes compared with wild type
RME-8 expressing cells (Fig. 3.7, B and F). In concert with RME-8 W20A failing to
associate with PI(3)P-positive endosomes, the clear increased accumulation of clathrin at
EEA1-positive structures compared with wild type and control cells points to RME-8
W20A possibly behaving as a dominant negative mutant. RME-8 W20A can still
associate with Hsc70 (Fig. 3.6A) and thus likely competes with endogenous RME-8 for
Hsc70, resulting in clathrin remaining at early endosomes. Thus, our results suggest that
RME-8 binding to PI(3)P through its PI(3)P-binding motif plays a critical mechanistic
role in regulating early endosomal clathrin levels in collaboration with its binding partner
Hsc70.
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Figure 3.7. RME-8 PI(3)P binding affects early endosomal clathrin dynamics.
Continued.
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Figure 3.7. RME-8 PI(3)P binding affects early endosomal clathrin dynamics.
Continued.
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Figure 3.7. RME-8 PI(3)P binding affects early endosomal clathrin dynamics.
Continued.
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Figure 3.7. RME-8 PI(3)P binding affects early endosomal clathrin dynamics. HeLa
cells were transiently transfected with wild type RME-8 (blue) (A) and RME-8
W20A(blue) (B) and for 24 h. Cells were triple-stained to observe endogenous EEA1
(red) and endogenous endosomal clathrin (green). A, wild type RME-8 at EEA1 early
endosomes is displayed as magenta colored puncta, and clathrin at EEA1 early
endosomes is displayed as yellow puncta. EEA1-positive and RME-8-positive endosomes
display reduced clathrin levels indicated by arrows, and early endosomes devoid of wild
type RME-8 (shown by arrowheads) display strong co-localization between EEA1 and
clathrin. B, cells expressing RME-8 W20A display high co-localization between clathrin
and EEA1. C, control cells are stained for endogenous RME-8 (blue), EEA1 (red), and
clathrin (green). D and E, HeLa cells were transfected with siRNA targeting RME-8 (D)
and SNX1 (E). Cells were stained for RME-8 (blue), EEA1 (red), and clathrin (green) to
observe clathrin accumulation at EEA1 positive endosomes. F, Pearson’s correlation
coefficient (PC) was utilized to quantify the extent of co-localization between clathrin
and EEA-1 in control, wild type RME-8, RME-8 W20A variant, RME-8 KD, and SNX1
KD samples. Means ±S.D. from three independent experiments (n = 30 cells) are shown.
p values were calculated by the Student’s t test and compared with wild type RME-8. **,
p < 0.01. The values of Pearson’s correlation coefficients of all the experiments were
related and compared with RME-8 W20A set at 100% due to its largest statistical value.
Solid white arrows, arrowheads, and expanded boxes represent regions of interest.
Images were collected using a X40 objective. Scale bars, µ15m.
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3.3.5. Perturbation of mannose 6-phosphate receptor localization by the RME-8 W20A PI(3)Pbinding mutant

Clathrin and retromer coats have been implemented in the retrograde transport of
transmembrane proteins from early endosomes to the trans-Golgi network (TGN) [84].
The action of these two coats working in a coordinated sequential fashion is facilitated by
the RME-8/Hsc70-mediated clathrin uncoating process at early endosomes [83, 84, 86,
105]. RME-8 is a component of the retromer coat, and it has been shown to be important
for the retrograde transport of transmembrane proteins such as the CIMPR [81, 83, 86].
The sorting of the acid hydrolase precursors starts at the TGN, and their delivery to early
endosomes is mediated by their binding to CI-MPR embedded in the membrane followed
by retrograde recovery of CI-MPR back to the TGN [81, 106, 129]. Proper functioning of
the retrograde transport is regulated by RME-8. Knockdown of RME-8 expression has
been shown to mis-sort retrograde transport receptors such as MIG-14 in C. elegans and
CI-MPR in mammalian cells [83, 86, 95]. Because RME-8 regulates CI-MPR transport
through clathrin disassembly [86], we investigated whether CI-MPR sorting would be
affected in cells expressing RME-8 PI(3)P binding mutants. Therefore, HeLa cells
expressing wild type RME-8 and RME-8 W20A were stained for endogenous CIMPR. In
control cells as well as in cells expressing wild type RME-8, CI-MPR was observed to
display mainly a perinuclear localization pattern with moderate staining at dispersed
cytoplasmic punctate consistent with previous reports on the steady state localization of
CI-MPR to TGN and endosomal structures [129-131]. However, in RME-8 W20Aexpressing cells, CI-MPR localization on cytoplasmic punctate structures was
significantly diminished and was predominantly found in the perinuclear region (Fig. 3.8,
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A and B ). The observed localization shift of CI-MPR was similarly reported in studies
where RME-8 expression was knocked down using siRNA [83, 95]. Analogous results
have also been reported when other members of retromer components were knocked
down in mammalian cells [106, 129]. In these studies, it was concluded that disruption of
retrograde transport of CI-MPR from endosomes to TGN results in rapid degradation of
CI-MPR due to re-routing of CI-MPR from the endosome to the lysosome. This results in
the loss of CI-MPR localization on endocytic punctate structures and the observed
perinuclear localization pattern [83, 95, 106, 129]. Thus, as a control, we examined HeLa
cells treated with siRNA targeting RME-8 and SNX1 (Fig. 3.8,C-E). Under these
conditions, we also observed a significant decrease in CI-MPR localized to punctate
structures, confirming previous studies and supporting the RME-8 W20A result. Overall,
our results demonstrate that PI(3)P association is critical for RME-8 cellular activities, as
disrupting the PI(3)P binding ability of RME-8 yields a phenotype resembling knocking
down RME-8 or SNX1 protein levels.
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Figure 3.8. Alteration of CI-MPR cellular localization in RME-8 W20A
expressing cells. Continued.
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Figure 3.8. Alteration of CI-MPR cellular localization in RME-8 W20A
expressing cells. Continued.
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Figure 3.8. Alteration of CI-MPR cellular localization in RME-8 W20A expressing
cells. A, HeLa cells expressing wild type RME-8 and RME-8 W20A were stained for
endogenous CI-MPR. Cells were analyzed by confocal microscopy. Images were
collected using a X40 objective. Scale bars, 15 µm. ImageJ was utilized to count the
number of total punctate in negative control, wild type RME-8, and RME-8 W20Atransfected cells. HeLa cells expressing RME-8 W20A exhibit a large decrease in the
peripheral number of CI-MPR positive punctate displaying perinuclear localization. B,
means ±S.D. of three independent experiments (n=30 cells) are shown. p values were
compared with wild type RME-8. **, p < 0.01. C and D, both RME-8 and SNX1depleted HeLa cells have been labeled with CI-MPR antibody and also displayed a
decrease in the total number of CI-MPR-positive punctate. E, bar graph representing the
effect that RME-8 KD and SNX1 KD p values were compared with WT RME-8 in A and
to negative control in C and D. All cells were analyzed by confocal microscopy. Means ±
S.D. of three independent experiments (n = 30 cells) are shown. p values were calculated
by Student’s t test and compared with wild type RME-8 and SNX1. ***, p < 0.001.
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3.3.6. SNX1 rescues RME-8 W20A dispersed cellular localization

The retromer complex is important in recognizing the cytosolic tail of MPRs for
efficient transport from endocytic structures [129]. The retromer constituent SNX1 is a
PX domain containing PI(3)P-binding protein [105, 125] that has been shown to play a
role in sensing and driving membrane curvature [83, 86, 105]. RME-8 associates with
SNX1 through a region C-terminal to its DnaJ domain, containing the third IWN repeat
and the linker region between the third and the fourth IWN repeat [86]. To examine the
relationship between the PI(3)P binding ability of RME-8 and its association with SNX1,
we co-transfected HeLa cells with wild type SNX1/RME-8 and variants of both that are
defective in PI(3)P association. As expected, wild type RME-8 and SNX1 strongly colocalize on peripheral structures consistent with endocytic vesicles (Fig. 3.9B).
Surprisingly, cells co-expressing both RME-8 W20A and wild type SNX1 exhibited a
drastic reversal in the RME-8 W20A subcellular localization pattern from diffused
cytoplasmic to punctate (Fig. 3.9, A and B). Moreover, the rescued RME-8 W20A
mutant strongly co-localizes with wild type SNX1. We next examined whether wild type
RME-8 could rescue a well characterized PX domain point mutant of SNX1 (K214A)
that disrupts PI(3)P binding [124, 132]. As shown in Fig. 3.9B, SNX1 K214A remains
diffusely localized throughout the cytoplasm when co-expressed with wild type RME-8,
indicating that RME-8 is not able to recover the PI(3)P-mediated localization of SNX1 to
endocytic structures when its PX domain is compromised. More striking, however, was
the observation that when co-expressed, SNX K124A induced significant loss of
endocytic localization of wild type RME-8 (Fig. 3.9B). One possible interpretation of this
result is that RME-8 requires SNX1 to localize to endocytic structures. To test this
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hypothesis, we utilized a C-terminal deletion mutant of RME-8 (RME-8 Δ C1165) that
lacks the SNX1 binding region and thus is unable to associate with SNX1 (6). However,
this deletion construct possesses the N-terminal PI(3)P-binding motif. When analyzed for
localization, RME-8 ΔC1165 was fully competent at targeting to peripheral punctate
structures (Fig. 3.9, A and C). Moreover, overexpression of SNX1 K124A failed to
disrupt localization of RME-8 ΔC1165 indicating that the PI(3)P-binding motif is
sufficient for localization to endocytic vesicles. Interestingly, RME-8 ΔC1165 and wild
type SNX1 strongly co-localized to these punctate structures suggesting that their
interaction is not required for targeting to these vesicles. To test this hypothesis without
the use of overexpressed proteins, we examined endogenous RME-8 localization in cells
treated with SNX1 siRNA (Fig. 3.10). We observed no significant alteration in the RME8 localization pattern in SNX1-depleted cells, confirming that RME-8 does not require
SNX1 for endosomal localization. We also investigated the effect of knocking down
RME-8 protein levels on SNX1 subcellular localization. As shown in Fig. 3.10, although
SNX1 was still observed on endocytic structures, there was a significant increase in
SNX1 tubulation in RME-8 depleted cells. An increase in SNX1 tubulation in response to
RME-8 depletion has been reported by others and is thought to represent stalled cargo
sorting [83, 133], indicating the importance of RME-8 to retromer-mediated trafficking
events.
The above results are intriguing as they reveal that although RME-8 endosomal
targeting is mediated through its PI(3)P binding motif, its interaction with SNX1 can also
affect its endosomal association. A possible explanation for these observations is that the
SNX1/RME-8 interaction could be simply stronger than the PI(3)P/RME-8 association,
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which could explain why the PX mutant of SNX1 was able to remove wild type RME-8
from endocytic structures, whereas wild type SNX1 was able to maintain RME-8 W20A
at these vesicles (Fig. 3.9B). Additionally, the SNX1 interaction may stabilize RME-8 at
the early endosome or perhaps serve an allosteric role during clathrin disassembly.
Although further studies are required, our results indicate the intriguing possibility that
regulatory mechanisms acting on SNX1 PI(3)P association (post-translational
modifications and protein/protein interactions) will also potentially regulate RME-8 and
subsequently Hsc-70-mediated clathrin disassembly.
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Figure 3.9. SNX1 expression affects RME-8 early endosome targeting.
Continued.
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Figure 3.9. SNX1 expression affects RME-8 early endosome targeting. Continued.
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Figure 3.9. SNX1 expression affects RME-8 early endosome targeting. A–C, HeLa
cells were transfected with the indicated constructs and analyzed by confocal microscopy.
Co-localizations between RME-8 and SNX1 variants are shown with arrows depicting
regions of co-localization. In the middle panel, HeLa cells were co-transfected with
RME-8 W20A and wild type SNX1, and arrows display regions of co-localization.
Images were collected using a X40 objective. Expanded boxes represent regions of
interest. Scale bars, 15 µm. D, quantitation of co localization between RME-8 and SNX1.
Means ± S.D. of three independent experiments (n = 30 cells) are shown. p values were
calculated by Student’s t test and compared with wild type RME 8 and SNX1, **, p <
0.01; ***, p < 0.001.
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Figure 3.10. RME-8 expression regulates SNX1 tubulation. A, HeLa cells were
transfected with RME-8 siRNA and SNX1 siRNA for 48 h. Knockdown of SNX1 protein
expression does not affect RME-8 endosomal localization (middle panel). Knockdown of
RME-8 protein expression results in the formation of SNX1- positive tubules (bottom
panel). Images were collected using a X60 objective. Expanded boxes represent regions
of interest. Scale bars, 15 _m. B, bar graph representation of the percentage of cells
altering from punctate to tubules in response to knockdown of RME-8 expression. Means
±S.D. of three independent experiments (n = 30 cells). p values were calculated by
Student’s t test and compared with control cells. *, p < 0.1.
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In conclusion, we have shown that RME-8 associates with PI(3)P-positive
endosomes through an N-terminal PI(3)P binding motif predicted to adopt a PH-like fold
and characterized by the presence of conserved basic and aromatic residues. The data
support the notion that RME-8 at PI(3)P-rich early endosomes facilitates the process of
clathrin removal, and the failure to do so may alter retrograde transport of cargo such as
CI-MPR. Our results are consistent with a previous study reporting that RME-8 is located
in SNX1-positive, clathrin negative subdomains [105]. This study by McGough and
Cullen [105] elegantly showed that clathrin is not required for SNX1-BAR tubulation
during retrograde transport as SNX1-BAR tubules start forming at RME-8-positive,
SNX1-positive, and clathrin-negative subdomains of the early endosomes. Because
RME-8 has not been found to be present in the tubules themselves, it indicates that it
likely plays a proximal role mainly at the endosomal level when clathrin is present.
Collectively, our data extend this model by which RME-8 utilizes PI(3)P binding in its
role in shedding off clathrin before SNX1-BAR tabulation takes place in the retrograde
transport pathway.

101

3.4. References
50. Lemmon, M. A. (2008) Membrane recognition by phospholipid-binding domains,
Nature reviews Molecular cell biology. 9, 99-111.
54. Mukherjee, S., Ghosh, R. N. & Maxfield, F. R. (1997) Endocytosis, Physiological
reviews. 77, 759-803.
55. Mellman, I. (1996) Endocytosis and molecular sorting, Annual review of cell and
developmental biology. 12, 575-625.
56. Conner, S. D. & Schmid, S. L. (2003) Regulated portals of entry into the cell,
Nature. 422, 37-44.
62. Chang, H. C., Hull, M. & Mellman, I. (2004) The J-domain protein Rme-8 interacts
with Hsc70 to control clathrin-dependent endocytosis in Drosophila, The Journal of cell
biology. 164, 1055-64.
68. Gonzalez-Gaitan, M. & Stenmark, H. (2003) Endocytosis and signaling: a
relationship under development, Cell. 115, 513-21.
71. Braulke, T. & Bonifacino, J. S. (2009) Sorting of lysosomal proteins, Biochimica et
biophysica acta. 1793, 605-14.
79. Johannes, L. & Popoff, V. (2008) Tracing the retrograde route in protein trafficking,
Cell. 135, 1175-87.
81. Bonifacino, J. S. & Hurley, J. H. (2008) Retromer, Curr Opin Cell Biol. 20, 427-36.
83. Popoff, V., Mardones, G. A., Bai, S. K., Chambon, V., Tenza, D., Burgos, P. V., Shi,
A., Benaroch, P., Urbe, S., Lamaze, C., Grant, B. D., Raposo, G. & Johannes, L. (2009)
Analysis of articulation between clathrin and retromer in retrograde sorting on early
endosomes, Traffic. 10, 1868-80.
84. Popoff, V., Mardones, G. A., Tenza, D., Rojas, R., Lamaze, C., Bonifacino, J. S.,
Raposo, G. & Johannes, L. (2007) The retromer complex and clathrin define an early
endosomal retrograde exit site, Journal of cell science. 120, 2022-31.
86. Shi, A., Sun, L., Banerjee, R., Tobin, M., Zhang, Y. & Grant, B. D. (2009)
Regulation of endosomal clathrin and retromer-mediated endosome to Golgi retrograde
transport by the J-domain protein RME-8, The EMBO journal. 28, 3290-302.
87. McGough, I. J. & Cullen, P. J. (2011) Recent advances in retromer biology, Traffic.
12, 963-71.
88. Ungewickell, E., Ungewickell, H., Holstein, S. E., Lindner, R., Prasad, K., Barouch,
W., Martin, B., Greene, L. E. & Eisenberg, E. (1995) Role of auxilin in uncoating
clathrin-coated vesicles, Nature. 378, 632-5.
102

89. Zhang, Y., Grant, B. & Hirsh, D. (2001) RME-8, a conserved J-domain protein, is
required for endocytosis in Caenorhabditis elegans, Molecular biology of the cell. 12,
2011-21.
90. Fujibayashi, A., Taguchi, T., Misaki, R., Ohtani, M., Dohmae, N., Takio, K.,
Yamada, M., Gu, J., Yamakami, M., Fukuda, M., Waguri, S., Uchiyama, Y., Yoshimori,
T. & Sekiguchi, K. (2008) Human RME-8 is involved in membrane trafficking through
early endosomes, Cell structure and function. 33, 35-50.
95. Girard, M., Poupon, V., Blondeau, F. & McPherson, P. S. (2005) The DnaJ-domain
protein RME-8 functions in endosomal trafficking, J Biol Chem. 280, 40135-43.
98. Silady, R. A., Kato, T., Lukowitz, W., Sieber, P., Tasaka, M. & Somerville, C. R.
(2004) The gravitropism defective 2 mutants of Arabidopsis are deficient in a protein
implicated in endocytosis in Caenorhabditis elegans, Plant physiology. 136, 3095-103;
discussion 3002.
99. Vilarino-Guell, C., Rajput, A., Milnerwood, A. J., Shah, B., Szu-Tu, C., Trinh, J.,
Yu, I., Encarnacion, M., Munsie, L. N., Tapia, L., Gustavsson, E. K., Chou, P.,
Tatarnikov, I., Evans, D. M., Pishotta, F. T., Volta, M., Beccano-Kelly, D., Thompson,
C., Lin, M. K., Sherman, H. E., Han, H. J., Guenther, B. L., Wasserman, W. W., Bernard,
V., Ross, C. J., Appel-Cresswell, S., Stoessl, A. J., Robinson, C. A., Dickson, D. W.,
Ross, O. A., Wszolek, Z. K., Aasly, J. O., Wu, R. M., Hentati, F., Gibson, R. A.,
McPherson, P. S., Girard, M., Rajput, M., Rajput, A. H. & Farrer, M. J. (2013) DNAJC13
mutations in Parkinson disease, Hum Mol Genet.
100. Walsh, P., Bursac, D., Law, Y. C., Cyr, D. & Lithgow, T. (2004) The J-protein
family: modulating protein assembly, disassembly and translocation, EMBO reports. 5,
567-71.
101. Lemmon, S. K. (2001) Clathrin uncoating: Auxilin comes to life, Current biology :
CB. 11, R49-52.
102. Brodin, L., Low, P. & Shupliakov, O. (2000) Sequential steps in clathrin-mediated
synaptic vesicle endocytosis, Current opinion in neurobiology. 10, 312-20.
103. Scheele, U., Alves, J., Frank, R., Duwel, M., Kalthoff, C. & Ungewickell, E. (2003)
Molecular and functional characterization of clathrin- and AP-2-binding determinants
within a disordered domain of auxilin, J Biol Chem. 278, 25357-68.
104. Brodsky, F. M., Chen, C. Y., Knuehl, C., Towler, M. C. & Wakeham, D. E. (2001)
Biological basket weaving: formation and function of clathrin-coated vesicles, Annual
review of cell and developmental biology. 17, 517-68.
105. McGough, I. J. & Cullen, P. J. (2013) Clathrin is not required for SNX-BARretromer-mediated carrier formation, Journal of cell science. 126, 45-52.

103

106. Seaman, M. N. (2004) Cargo-selective endosomal sorting for retrieval to the Golgi
requires retromer, The Journal of cell biology. 165, 111-22.
107. Verges, M. (2007) Retromer and sorting nexins in development, Frontiers in
bioscience : a journal and virtual library. 12, 3825-51.
108. Xhabija, B., Taylor, G. S., Fujibayashi, A., Sekiguchi, K. & Vacratsis, P. O. (2011)
Receptor mediated endocytosis 8 is a novel PI(3)P binding protein regulated by
myotubularin-related 2, FEBS Lett. 585, 1722-8.
109. Chenna, R., Sugawara, H., Koike, T., Lopez, R., Gibson, T. J., Higgins, D. G. &
Thompson, J. D. (2003) Multiple sequence alignment with the Clustal series of programs,
Nucleic acids research. 31, 3497-500.
110. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. (2015)
The Phyre2 web portal for protein modeling, prediction and analysis, Nature protocols.
10, 845-58.
111. Kelley, L. A. & Sternberg, M. J. (2009) Protein structure prediction on the Web: a
case study using the Phyre server, Nature protocols. 4, 363-71.
112. Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L. & Schwede, T. (2009) The SWISSMODEL Repository and associated resources, Nucleic acids research. 37, D387-92.
113. Guex, N. & Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an
environment for comparative protein modeling, Electrophoresis. 18, 2714-23.
114. Bolte, S. & Cordelieres, F. P. (2006) A guided tour into subcellular colocalization
analysis in light microscopy, Journal of microscopy. 224, 213-32.
115. Saltel, F., Mortier, E., Hytonen, V. P., Jacquier, M. C., Zimmermann, P., Vogel, V.,
Liu, W. & Wehrle-Haller, B. (2009) New PI(4,5)P2- and membrane proximal integrinbinding motifs in the talin head control beta3-integrin clustering, The Journal of cell
biology. 187, 715-31.
116. Martel, V., Racaud-Sultan, C., Dupe, S., Marie, C., Paulhe, F., Galmiche, A., Block,
M. R. & Albiges-Rizo, C. (2001) Conformation, localization, and integrin binding of talin
depend on its interaction with phosphoinositides, J Biol Chem. 276, 21217-27.
117. Wurmser, A. E. & Emr, S. D. (2002) Novel PtdIns(3)P-binding protein Etf1
functions as an effector of the Vps34 PtdIns 3-kinase in autophagy, The Journal of cell
biology. 158, 761-72.
118. Kutateladze, T. G., Ogburn, K. D., Watson, W. T., de Beer, T., Emr, S. D., Burd, C.
G. & Overduin, M. (1999) Phosphatidylinositol 3-phosphate recognition by the FYVE
domain, Molecular cell. 3, 805-11.

104

119. Busse, R. A., Scacioc, A., Hernandez, J. M., Krick, R., Stephan, M., Janshoff, A.,
Thumm, M. & Kuhnel, K. (2013) Qualitative and quantitative characterization of proteinphosphoinositide interactions with liposome-based methods, Autophagy. 9, 770-7.
120. Gillooly, D. J., Raiborg, C. & Stenmark, H. (2003) Phosphatidylinositol 3phosphate is found in microdomains of early endosomes, Histochemistry and cell
biology. 120, 445-53.
121. Lee, S. A., Eyeson, R., Cheever, M. L., Geng, J., Verkhusha, V. V., Burd, C.,
Overduin, M. & Kutateladze, T. G. (2005) Targeting of the FYVE domain to endosomal
membranes is regulated by a histidine switch, Proc Natl Acad Sci U S A. 102, 13052-7.
122. Bravo, J., Karathanassis, D., Pacold, C. M., Pacold, M. E., Ellson, C. D., Anderson,
K. E., Butler, P. J., Lavenir, I., Perisic, O., Hawkins, P. T., Stephens, L. & Williams, R.
L. (2001) The crystal structure of the PX domain from p40(phox) bound to
phosphatidylinositol 3-phosphate, Molecular cell. 8, 829-39.
123. Ellson, C. D., Andrews, S., Stephens, L. R. & Hawkins, P. T. (2002) The PX
domain: a new phosphoinositide-binding module, Journal of cell science. 115, 1099-105.
124. Cozier, G. E., Carlton, J., McGregor, A. H., Gleeson, P. A., Teasdale, R. D., Mellor,
H. & Cullen, P. J. (2002) The phox homology (PX) domain-dependent, 3phosphoinositide-mediated association of sorting nexin-1 with an early sorting
endosomal compartment is required for its ability to regulate epidermal growth factor
receptor degradation, J Biol Chem. 277, 48730-6.
125. Gallop, J. L. & McMahon, H. T. (2005) BAR domains and membrane curvature:
bringing your curves to the BAR, Biochemical Society symposium, 223-31.
126. Misra, S. & Hurley, J. H. (1999) Crystal structure of a phosphatidylinositol 3phosphate-specific membrane-targeting motif, the FYVE domain of Vps27p, Cell. 97,
657-66.
127. Koumandou, V. L., Boehm, C., Horder, K. A. & Field, M. C. (2013) Evidence for
recycling of invariant surface transmembrane domain proteins in African trypanosomes,
Eukaryotic cell. 12, 330-42.
128. Eisenberg, E. & Greene, L. E. (2007) Multiple roles of auxilin and hsc70 in
clathrin-mediated endocytosis, Traffic. 8, 640-6.
129. Arighi, C. N., Hartnell, L. M., Aguilar, R. C., Haft, C. R. & Bonifacino, J. S. (2004)
Role of the mammalian retromer in sorting of the cation-independent mannose 6phosphate receptor, The Journal of cell biology. 165, 123-33.
130. Geuze, H. J., Stoorvogel, W., Strous, G. J., Slot, J. W., Bleekemolen, J. E. &
Mellman, I. (1988) Sorting of mannose 6-phosphate receptors and lysosomal membrane
proteins in endocytic vesicles, The Journal of cell biology. 107, 2491-501.
105

131. Klumperman, J., Hille, A., Veenendaal, T., Oorschot, V., Stoorvogel, W., von
Figura, K. & Geuze, H. J. (1993) Differences in the endosomal distributions of the two
mannose 6-phosphate receptors, The Journal of cell biology. 121, 997-1010.
132. Zhong, Q., Lazar, C. S., Tronchere, H., Sato, T., Meerloo, T., Yeo, M., Songyang,
Z., Emr, S. D. & Gill, G. N. (2002) Endosomal localization and function of sorting nexin
1, Proc Natl Acad Sci U S A. 99, 6767-72.
133. Seaman, M. & Freeman, C. L. (2014) Analysis of the Retromer complex-WASH
complex interaction illuminates new avenues to explore in Parkinson disease,
Communicative & integrative biology. 7, e29483.

106

CHAPTER 4

107

CHAPTER 4
DIFFERENTIAL PHOSPHORYLATION OF THE PHOSPHOINOSITIDE 3PHOSPHATASE MTMR2 REGULATES ITS ASSOCIATION WITH EARLY
ENDOSOMAL SUBTYPES
4.1. Introduction

Although

the

majority

of

protein

tyrosine

phosphatases

(PTPs)

use

phosphotyrosine-containing proteins as substrates, the active myotubularin (MTM)
family members dephosphorylate the lipid second messengers phosphoinositol 3phosphate [PI(3)P and PI(3,5)P2] [22, 33, 34, 36]. These phosphoinositols mainly reside
on endocytic structures and play key roles in membrane targeting, vesicular trafficking,
and regulation of signal transduction pathways by interacting and recruiting distinct
signaling proteins containing appropriate phosphoinositol-binding module(s) [47, 134,
135]. The importance of regulating phosphoinositol phosphorylation is highlighted by the
fact that loss of function mutations in three mtmr genes has been associated with distinct
neuromuscular disorders [38, 40, 136]. For example, the gene encoding MTMR2 is
mutated in Charcot–Marie-Tooth (CMT) disease 4B, an autosomal recessive
demyelinating disorder, characterized by abnormally folded myelin sheaths, inadequate
nerve signaling to muscles, and eventual muscle weakness and atrophy [38]. Despite the
fact that pathophysiological consequences resulting from loss of MTMR2 function are
well established, how MTMR2 participates in trafficking events remains poorly
understood. Intriguingly, under typical cell culture conditions, MTMR2 is not widely
localized to the endosomal structures containing its substrates PI(3)P and PI(3,5)P2.
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Recently, our laboratory used mass spectrometry to identify a prominent
phosphorylation site at Ser58 that is close to the PH-GRAM domain of MTMR2 [53].
Functional characterization of this modification demonstrated that phosphorylation
dramatically regulates MTMR2 endosomal localization and thus access to its lipid
substrates [53]. Specifically, mass spectrometry analysis suggested that the soichiometry
of phosphorylation at Ser58 was greater than 50%, providing evidence that MTMR2
Ser58 may be highly phosphorylated during normal cell growth conditions. A
phosphorylation deficient variant (MTMR2 S58A) displays strong endosomal
localization with Rab5-positive vesicles resulting in efficient depletion of PI(3)P and an
increase in growth factor receptor signaling pathways, most notably the extracellular
signal-regulated kinase (ERK). Therefore, reversible phosphorylation represents a critical
mechanism regulating the endosomal targeting of MTMR2 and provides valuable insight
into how MTMR2 activity toward its lipid substrates can be spatially and temporally
controlled. However, the exact mechanism of MTMR2 phosphorylation, including
identification of the responsible kinase, remains to be elucidated.
The Rab5 GTPase is a master coordinator of early endosome maturation events
including homotypic early endosome fusion as well as heterotypic early to late endosome
fusion [137, 138]. Furthermore, Rab5 collaborates with numerous peripheral endosome
binding proteins to facilitate fusion of endosome membranes including Rab5 effectors
whose endosome targeting requires association with endosomal PI(3)P [139-142]. This
property reveals that the endosomal activities of Rab5 can be dramatically affected by
PI(3)P levels. For example, the critical endosomal effectors Rabenosyn-5 and Early
Endosomal Antigen 1 (EEA1) are essential tethering factors important for endosome
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fusion events [139-142]. These effectors require association with Rab5 and PI(3)P
simultaneously to localize to early endosomes. Recently it has been shown that
endosomes rich in the adaptor protein containing a pleckstrin homology domain,
phosphotyrosine binding domain and a leucine zipper motif (APPL1) represent a critical
stage during attenuation of receptor signaling and initiation of early endosome
maturation. It has been demonstrated that when PI(3)P is depleted using the PI(3)K
inhibitor wortmannin, Rab5/ EEA1-positive early endosomes are converted to
Rab5/APPL1- positive early endosomes [143]. Interestingly, the Rab5/APPL1 endosomes
displayed a delay in endosomal maturation and enhanced growth factor endosomal
signaling capability [143]. In addition to functioning as a Rab5 effector and as a regulator
of endosomal signaling, APPL1 serves as a stage marker for proximal early endosomes
[144]. The shedding of APPL1 as vesicles move centrally coincides with increased levels
of PI(3)P, recruitment of EEA1 and subsequent maturation into the canonical
PI(3)P/Rab5-positive endosomes [143, 145]. Since APPL1 vesicles are known to play a
functional role in the assembly of signaling complexes for MAPK and Akt pathways,
increased levels of PI(3)P acts as a molecular switch to turn off growth factor endosomal
signaling through the simultaneous loss of APPL1 on these endosomes. In this study, we
provide evidence that ERK1/2 is the Ser58 kinase and thus may regulate endosomal
targeting of MTMR2 via a negative feedback loop. Moreover, we have characterized a Cterminal phosphorylation site at position Ser631 that regulates the targeting of MTMR2
to APPL1-rich endosomes presenting a mechanism through which MTMR2 can shuttle
between different endosomal compartments to target different pools of PI(3)P.
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4.2. Materials and Methods

4.2.1. Plasmids, cell culture and transfections

The synthesis of pCDNA3.1-NF and pET21a vectors containing wild type and
mutant FLAG-MTMR2 or MTMR2-His6 constructs have been previously described [34,
53]. Generation of S631A and S631E mutant variants were preformed similar to that
described for S58A, S58E and C417S [53] using PCR based site-directed mutagenesis.
The

forward

primer

for

the

generation

of

S631A

used

was

5’-

GAGAGAGCCAGCGCTCCTGCACAGTG-3’ while the reverse primer was 5’CACTGTGCAGGAGCGCTGGCTCTCTC-3’. The forward primer for the generation of
S631E used was 5’- CAGAGAGAGCCAGCGAGCCTGCACAGTGTGTC- 3’ while the
reverse primer was 5’- GACACACTGTGCAGGCTCGCTGGCTCTCTCTG- 3’. The
constructs generated include S58A/S631A, S58A/ S631E, S58E/S631A, S58E/S631E,
S58A/C417S/S631A and S58A/C417S/S631E and were verified by DNA sequencing
(ACGT Corp. and Bio Basic Inc.). The human cell culture lines HEK293 (ATCC) and
HeLa (ATCC) were cultured and transfected with constructs as described previously [53].
HEK293 cells were selected for reproducible transfections efficiency for the cell
signaling experiments while HeLa cells were utilized for immunofluorescence
microscopy studies to better resolve endosomal compartments. The pEFGP- 2XFYVE
construct was a generous gift from Harald Stenmark [146].
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4.2.2. Production of MTMR2 Ser58 phospho-specific antibody

The target peptide epitope was synthesized (NEO BioScience), resuspended in
conjugation buffer (100 mM NaPO4, 150 mM NaCl, 5 mM EDTA, pH 7.3), reduced with
immobilized TCEP and conjugated to maleimide-activated Keyhole limpet hemocyanin
(Pierce Biotechnology) through an engineered thiol terminal. The formulated carrier was
then used for immunization of Gallus gallus (Amicus Biotech). Purified polyclonal
chicken anti-pSer58 IgY antibodies were isolated by the water dilution method followed
by

subtractive

affinity

chromatography

against

non-phophosphorylated

and

phosphorylated peptide epitopes immobilized on iodoacetamide-activated agarose (Pierce
Biotechnology) conjugated by similar method described above. Antibody specificity was
tested against both MTMR2 peptide and protein epitopes by standard dot and
immunoblot procedures. Briefly, peptides or FLAG-MTMR2 immunoprecipitates (as
described below) were treated with or without 2.5 U of calf intestinal alkaline
phosphatase (Promega) for 4–6 hours at 25°C shaking, then spotted on nitrocellulose for
peptide dot blot analysis or prepared for immunoblotting as described below and by [53].
Membranes were blocked with 5% BSA in TBST, probed with chicken antipSer58 IgY at
1:1000 (0.7 mg/ml stock) in 2% BSA TBST, washed, then probed with donkey anti-IgY
HRP conjugate at 1:3000 (Gallus Immunotech) in 2% BSA TBST for subsequent
imaging.

4.2.3. In vitro kinase assay

In vitro kinase assays were performed using 5 mg of bacterial recombinant
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MTMR2-His6 proteins purified as described previously [147]. In this study, the activated
kinases ERK1, ERK2, p38α, JNK1 (Signal Chem) were tested with all assays being
carried out in reaction buffer (25 mM HEPES, pH 7.2, 12.5 mM – β glycerol phosphate,
25 mM MgCl2, 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT) containing 200 mM ATP
and 100 ng of the specified kinase. Reactions were incubated shaking at 30°C for 30
minutes, terminated with 30 ml 2XSDS loading dye, boiled for 5 minutes, then 20 ng of
protein substrate was separated on a 10% polyacrylamide gel and probed with chicken
anti-pSer58 MTMR2 as described above, anti-MAPK (Sigma) at 1:10,000 in 1% skim
milk TBST and rabbit anti-p38 (Cell Signaling) at 1:1000 in 5% BSA/TBST overnight
4°C with goat anti-rabbit HRP conjugate (Bio-Rad) at 1:5000 in 2.5% BSA/TBST, along
with rabbit anti-JNK1 (Santa Cruz Biotechnology) at 1:1000 in 2.5% BSA TBST
overnight 4°C and mouse anti-MTMR2 (Santa Cruz Biotechnology) at 1:1000 in 1%
skimmed milk TBST with goat anti-mouse IgG HRP conjugate (Promega) at 1:5000 in
1% skim milk TBST.

4.2.4. siRNA and serum starvation treatment

HEK293 or HeLa cells were grown as described above and seeded into antibiotic
free medium 24 hours prior to transfection with either 35 nM Signal Silence H control
siRNA or SignalSilenceH p44/42 MAPK (ERK1/2) siRNA (Cell Signaling Technology).
Cells were also left untransfected for probing of endogenous MTMR localization and
Ser58 phosphorylation in response to serum starvation. After ,30 hours, both treated and
untreated cells were transfected with either FLAG S58A MTMR2 or MTMR2 and
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incubated for another ~30–36 hours. Cells were moved into low (0.5%) serum containing
medium for another 6–10 hours, followed by a short serum starvation and 10 minutes of
EGF stimulation as described below. Cells were then prepared for immunofluorescence
microscopy as described below (siRNA and endogenous serum starved treatments) or
washed, lysed and prepared for immunoblot analysis and/or immunoprecipitation (siRNA
and endogenous serum starved treatments). Immunofluorescence of siRNA experiments
were performed using primary antibodies rabbit anti-phospho-p44/ p42 MAPK(ERK1/2)
(Thr20Tyr204; Cell Signaling Technologies) at 1:50 and mouse anti-FLAG (below)
along with fluoroscein horse anti-mouse (Vector Laboratories) and Alexa Fluor 568 goat
anti-rabbit (Molecular Probes, Invitrogen) secondary antibodies at 1:500. Endogenous
studies were performed using rabbit anti-MTMR2 (a generous gift from Gregory S.
Taylor; University of Nebraska) and mouse anti-Rab5 (BD BioSciences) along with
FITC-conjugated goat antirabbit (Vector Laboratories) and Alexa Fluor 568 goat antimouse secondaries as below. Microscopy image analysis and acquisition is described
below. For immunoprecipitation, equal amounts of lysate were added to mouse antiMTMR2 (Santa Cruz Biotechnology) immobilized on protein-A–agarose (Thermo
Pierce; Invitrogen). Precipitation was allowed to go for approx. 6–8 hours, rotating at
4°C, followed by immunoblot analysis. Quantitative immunoblotting of both siRNA and
serum starvation experiments was performed using chicken anti-pSer58 MTMR2 (1:200),
mouse anti-MTMR2 (1:1000), mouse anti-FLAG (1:3000), rabbit antiphospho-p44/p42
MAPK (above; 1:200), rabbit anti-MAPK (1:10,000) and rabbit anti-actin (below;
1:1000) in either 2.5% BSA or skim milk. Secondary antibodies included donkey antiIgY-HRP, goat anti-mouse-HRP, goat anti-rabbit (all above; 1:5000) in either 1% or
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2.5% skimmed milk. Acquired chemiluminescent images from at least n53 independent
experiments

were

quantified

through

densitometry

using

ImageJ

(NIH,

http://imagej.nih.gov/ij). Resulting data was normalized to its respective actin loading
control and subjected to either a one-way ANOVA with Tukey’s post test or a two-tailed,
unpaired t-test statistical analysis both with 95% confidence intervals for relative
comparison of related proteins (ie. ERK1/2 versus pERK1/2 and FLAG-MTMR2 versus
pSer58 FLAG-MTMR2) using GraphPad Prism version 4.0 for Windows, GraphPad
Software, San Diego, California, USA, www.graphpad.com. Relative comparison among
all experimental and control samples was performed, with significance differences among
data sets being denoted by at least *P< 0.05. Data are represented as the mean value 6 ±
s.e.m.

4.2.5. Cell treatment with kinase inhibitors

HEK293 or HeLa cells were treated with a JNK inhibitor SP600125 (LC
laboratories) at 40 mM for 1 hour, a p38 inhibitor SB203580 (LC laboratories) at 20 mM
for 30 minutes or a MEK inhibitor U1026 to inhibit ERK1/2 activation (LC laboratories)
at 50 mM for 1 hour as indicated. For the phosphorylation studies, cells were first serum
starved for 30 minutes followed by pre-incubation with U0126, then subsequently
stimulated with EGF (5 ng/ml) for 5 or 30 minutes. Cells were lysed and samples purified
by FLAG-IP, separated by SDS-PAGE and subjected to immunoblotting analysis as
described [53]. Immunoblotting was performed to probe for both loading controls and to
confirm ERK1/2 inhibition using primary antibodies rabbit anti-MAPK (Sigma) at
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1:10,000 and PathScanH Multiplex Western Cocktail I (Cell signaling technology) at
1:200, mouse anti-FLAG (Sigma) at 1:3000 and rabbit anti-actin (Sigma) at 1:3000 as
described previously [53]. Phosphorylation at Ser58 of MTMR2 was determined using
primary chicken anti-pSer58 MTMR2 as described above and was quantified from three
independent experiments by densitometry using ImageJ, and normalized to FLAG (IP)
levels.

4.2.6. Immunofluorescence

For immunofluorescence, HeLa cells were fixed, permeabilized, pre-treated,
stained and imaged as previously described [53]. Cell treatment with kinase inhibitors
was preformed as described as above and as indicated. Primary antibodies included
mouse anti-FLAG (Sigma) at 1:500, rabbit anti-Rab5 (Santa Cruz) at 1:80, rabbit antiRab7 (Sigma) at 1:100 and rabbit anti-APPL1 (Santa Cruz) at 1:80. Secondary antibodies
included Alexa Fluor 568 goat antimouse (Molecular probes) at 1:500 and FITCconjugated goat anti-rabbit (Vector Laboratories) at 1:500. Images were acquired with a
Zeiss Axiovert 200M inverted fluorescent microscope with FITC/TRITC/DAPI filter
cubes and LD Plan-APONeofluar 636 0.75 or EC Plan-Neofluar 406 1.3 oil objectives
equipped with 103061300 monochrome CCD camera (Axiovision MRM) was also used.
Captured pictures from both microscopes were processed with Northern Eclipse software
6.0 (Empix, Mississauga, ON) with contrast/brightness and exposure image corrections
performed using program processing application software in addition to Adobe
Photoshop 7.0.
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4.2.7. Image analysis

To quantify the colocalization of selected proteins, Pearsons’s correlation
coefficient (PC) values were calculated using the JACoP plug-in [114] within ImageJ
(National Institutes of Health). A sample size of 30 cells for each MTMR2 construct was
examined for dual-channel colocalization and values representative of the average from
three independent experiments (n=30). A crosscorrelation analysis by shifting the green
image in x-direction pixel per pixel relative to the red image and calculating the
respective PC was used to analyze the colocalization of MTMR2 point mutants to
APPL1, Rab5 or EGFP 2X-FYVE. This analysis was not performed on images in which
the localization pattern was largely diffuse to avoid reporting false colocalization. This
method does not depend on the relative intensities of the two channels and therefore
alleviates the interpretation of true partial or complete colocalization to intermediate PC
values (range from -1 to 1: negative values not used for colocalization). All images
before automatic colocalization analysis from raw images were corrected post-acquisition
using mean background subtraction [148, 149].

4.3. Result

4.3.1. ERK 1/2 phosphorylates MTMR2 at position Ser58 in vitro

Phosphorylation of Ser58 strongly correlates to sequestration of MTMR2 away
from its physiological endosomal substrate PI(3)P [53]. The ability to monitor
phosphorylation levels of MTMR2 Ser58 would then reflect both the pseudoinactive state
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of MTMR2 towards this endosomal PI(3)P, and also provide an indirect measure of the
targeted endosomal PI(3)P levels. Furthermore, evidence of the responsible kinase(s)
would be key information to understanding the mechanisms that underlie this critical
regulatory event. To this end, we designed and generated a polyclonal phospho-specific
antibody, and using immunoblot analysis, characterized its phosphospecificity towards
MTMR2 Ser58 (Fig. 4. 1A,B). The antibody readily detects wild type MTMR2 while
treatment with alkaline phosphatase completely ablates the signal similar to that of
MTMR2 S58A, emphasizing phosphate-dependent recognition. Interestingly, the
phospho-specific antibody also detected MTMR2 S58E supporting our previous results
that this phosphomimetic mutant of MTMR2 functionally behaves like phosphorylated
MTMR2 [53].
Ser58 resides in a so-called SP motif, suggesting that MTMR2 is regulated by proline
directed kinases such as members of the mitogen activated protein kinase (MAPK)
family. As phosphorylation deficient MTMR2 localizes to endosomes and enhances
ERK1/2 activation [53], our hypothesis is that activated ERK1/2 may regulate MTMR2
in a negative feedback loop by phosphorylating Ser58 to induce MTMR2 release from
endosomes. As a first step towards testing this hypothesis, we employed in vitro kinase
assays, and using our Ser58 phospho-specific antibody, examined the ability of MTMR2
to be phosphorylated by distinct MAPK family members.
Recombinant MTMR2 was purified from bacterial cell lysates and in vitro kinase assays
using commercially available active MAPKs were performed. Following the kinase
assay, the proteins were separated by SDS/PAGE and phosphorylation of MTMR2 at
Ser58 was determined by immunoblot analysis using our phospho-Ser58 antibody (Fig.
118

4.1C). It was determined that both ERK1 and ERK2 could effectively phosphorylate
MTMR2 at Ser58 (Fig. 4.1C, upper panel). In contrast, neither recombinant JNK1 nor
p38α were able to detectably phosphorylate MTMR2 Ser58 in vitro.
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Figure 4. 1. In vitro phosphorylation of recombinant MTMR2 by ERK1/2. (A)
PhosphoSer58 and nonphosphoSer58 peptides were incubated with and without alkaline
phosphatase and spotted on nitrocellulose membrane and probed with pSer58 antibody.
(B) HEK293 cells were transfected with MTMR2 phospho-variants, FLAG
immunoprecipitated and probed for total MTMR2 (IB: FLAG) and phosphorylated
MTMR2 at Ser58 (IB: pSer58). UT, untreated. (C) Purified His6 bacterial recombinant
MTMR2 was the substrate in the in vitro MAPK kinase assay. Each reaction contained 5
mg of recombinant MTMR2, 100 ng of various kinases (top), 200 mM ATP and was
incubated at 30°C for 30 minutes. The phosphorylation of Ser58 MTMR2 was detected
using pSer58 antibody. Total MTMR2 levels were determined with a-MTMR2 antibody.
Reactions were probed for total kinase levels, which served as additional loading
controls. (D) HEK 293 cells expressing MTMR2 were transfected with control scramble
siRNA or MTMR2 with ERK1/2 siRNA and cultured as described in Materials and
Methods. Cells were stimulated with 5 ng/ml EGF for 10 minutes, lysed and analyzed by
immnunoblot analysis.
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While the kinase assays demonstrate direct phosphorylation in vitro, it was important to
examine the phosphorylation status of MTMR2 Ser58 in cells whose expression levels of
ERK1/2 have been reduced using small interfering RNA (siRNA). HEK293 cells
transfected with ERK1/2 siRNA were grown under low serum conditions for 6 hours
followed by a 10 minutes EGF stimulation before cell lysis. These conditions effectively
knocked down total ERK1/2 protein levels and greatly reduced the levels of active
phosphorylated ERK1/2 in the cells (Fig. 4.1D; for quantitation of the data, see Fig.
4.10). This reduction in ERK1/2 levels significantly decreased the phosphorylation levels
of MTMR2 at position Ser58 compared to control (~50% reduction), consistent with our
in vitro kinase assay implementing ERK1/2 as the responsible kinase for Ser58
phosphorylation.

4.3.2. Inhibition of ERK1/2 targets MTMR2 to endosomal structures

To obtain insight into the potential of ERK1/2 as a regulator of MTMR2
endosomal localization, we performed immunofluorescence experiments in HeLa cells
using various MAPK inhibitors to examine if attenuation of ERK1/2 activation would
alter the localization of wild type MTMR2. This would be evident by the occurrence of a
MTMR2 shift from the typical diffuse cytoplasmic pattern when phosphorylated [28, 31,
53, 150], to an endosomal punctate pattern exhibited by unphosphorylated MTMR2 [53].
Consistent with the in vitro kinase assays, inhibitors to JNK and p38 did not alter the
localization pattern of MTMR2 (Fig. 4.2F,H). However, when cells were treated with the
MAPK/ERK kinase (MEK) inhibitor U0126, to inhibit the ERK1/2 pathway, this
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dramatically re-localized MTMR2 to endosomal punctate structures, exhibiting a
localization pattern analogous to MTMR2 S58A (Fig. 4.2D). Moreover, when we
analyzed the localization of MTMR2 in ERK1/2 siRNA-treated HeLa cells, we observed
a similar shift of MTMR2 localization to endosomal punctate structures ( Fig. 4. 11).
These results indicate that inhibition of the ERK1/2 pathway in cellula elevates MTMR2
endosomal targeting presumably by preventing Ser58 phosphorylation.
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Figure 4. 2. Inhibition of the ERK1/2 pathway induces subcellular targeting of
MTMR2 to punctate regions. (A–J) HeLa cells were transiently transfected with
FLAG-MTMR2 or FLAG-MTMR2 S58A and treated with the MEK inhibitor U0126
(ERK1/2) at 50 mM for 1 hour, SB203580 (p38) at 20 mM for 30 minutes and SP600125
(JNK) at 40 mM for 1 hour. Cells were probed for FLAG-MTMR2 (red) using Alexa
Fluor 568. Boxes indicate regions of interest and are presented in expanded views.
Images were collected using 63X objectives. Scale bars: 15 µm.
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4.3.3. Phosphorylation of MTMR2 at Ser58 is greatly reduced following ERK1/2 inhibition

In response to various stimuli including growth factors such as epidermal growth
factor (EGF), ERK1/2 becomes activated by phosphorylation (pERK1/2), which in turns
leads to phosphorylation of downstream target substrates [151]. To complement the
immunofluorescence results, HEK293 cells expressing MTMR2 were treated with EGF
and examined for the effects on Ser58 phosphorylation following MEK inhibition (Fig.
4.3). Under control conditions, MTMR2 displayed high levels of phosphorylation at
position Ser58, which decreased following a 30-minute serum starvation period (Fig. 4.
3A). EGF stimulation transiently activated ERK1/2, detected by phosphorylation levels
of ERK1/2 (Fig. 4.3; Fig. 4. 12) and those of a downstream ERK1/2 substrate, S6 kinase
(pS6K). Under these conditions, MTMR2 Ser58 phosphorylation levels also increased
~2-fold compared to the untreated samples (Fig. 4.3B). Importantly, this observed
increase in Ser58 phosphorylation was strongly attenuated when EGF stimulated cells
were pre-treated with the MEK inhibitor (Fig. 4. 3).
These results, taken together with our in vitro kinase assay and the ERK1/2 knockdown
studies, strongly implicate ERK1/2 as a kinase capable of phosphorylating MTMR2 at
position Ser58 and potently regulating the endosomal localization of MTMR2.
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Figure 4. 3. Inhibition of the ERK1/2 pathway causes a decrease in Ser58 MTMR2
phosphorylation. (A) HEK293 cells were transiently transfected with FLAG-MTMR2
for 42 hours. Cells were serum starved (S.S) for 30 minutes then treated with the MEK
inhibitor U0126 to downregulate ERK1/2 activity (where indicated), followed by
stimulation with 5 ng/ml EGF for 5 or 30 minutes at 37°C. Cells were lysed and FLAG
immunoprecipitated (IP), then probed for phosphorylation of Ser58 MTMR2. FLAGMTMR2 immunoblotting (IB) of FLAG-IP was used to confirm equal transfections
levels. Total ERK1/2, actin and FLAG lysates served as loading controls. (B) MTMR2
Ser58 phosphorylation was quantified by densitometry using ImageJ and normalized to
total FLAG (IP). Representative western blots are shown in A. Means ± s.d. of the
results of three independent experiments are given, with the values representing fold
change relative to serum-starved control (s.s) without inhibitor. *P<0.05, **P<0.01 for
the comparisons indicated.
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4.3.4. Inhibition of JNK1 and ERK1/2 targets MTMR2 to APPL1 endosomes

Recent phosphoproteomic studies have mapped Ser631 as a phosphorylation site
on MTMR2 [152]. Interestingly, Ser631 also resides in a proline-directed consensus site
suggesting that a MAPK family member may also regulate this phosphorylation event.
Thus, we were interested in examining the endosomal localization pattern of MTMR2 in
response to different MAPK inhibitors (Fig. 4.4; Fig. 4.13). HeLa cells expressing
MTMR2 were treated with various MAPK inhibitors and examined for colocalization
with the early endosome marker Rab5. Untreated, MTMR2 displayed the characteristic
cytoplasmic staining pattern with greater intensity in the perinuclear region and lack of
any Rab5 localization (Fig. 4.4A, upper panel). When cells were treated with the MEK
inhibitor, MTMR2 displayed a punctate pattern with a subset of vesicles that were
positive for both MTMR2 and Rab5 (Fig. 4.4A, middle panel). The extent of Rab5
colocalization was similar to that observed with MTMR2 S58A and Rab5 where the
colocalized staining seem to be directly adjacent or on opposite sides of the same vesicle
[53]. Combined inhibition of JNK1 and MEK1/2 displayed a pronounced MTMR2
punctate pattern. However, these vesicles were completely void of Rab5 colocalization
and were noticeably enlarged (Fig. 4.4A, bottom panel; Table 4.1). Additionally,
combined inhibition of p38 and MEK1/2 resulted in a partial colocalization of MTMR2
and Rab5, a similar phenotype as the MEK inhibitor alone (Fig. 4.14).
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Figure 4.4. Inhibition of ERK1/2 and JNK pathways targets MTMR2 to APPL1positive endosomes. (A,B) HeLa cells were transiently transfected with FLAG-MTMR2
for 42 hours and analyzed by immunofluorescence microscopy. Cells were untreated (top
panel) or treated with the following inhibitors: U0126 alone (middle panel) or combined
with SP600125 (bottom panel). Cells were probed for FLAG MTMR2 (red) and
endogenous Rab5 (green) (A) or endogenous APPL1 (B). Solid white arrows indicate
regions of colocalization and open arrows indicate lack of vesicle colocalization and are
presented in expanded views. Images were collected using 63X objectives. Scale bars: 15
µm.
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Recently, APPL1 containing vesicles were shown to define an early transient endosome
subpopulation that resides downstream of clathrin-coated pits en route to PI(3)P-positive
early endosomes. PI(3)P depletion at the early endosomes resulted in reversion of
PI(3)P/Rab5 endosomes back to their preceding APPL1 endosomes with accompanying
vesicle enlargement [143]. Thus, we investigated whether the enlarged MTMR2-positive
endosomes observed in response to double MAPK inhibition were positive for APPL1
using co-immunofluorescence. As shown in Fig. 4B, HeLa cells expressing MTMR2
strongly colocalized with APPL1 when the cells were treated with the MEK1/2 and JNK1
inhibitors. However, inhibition of the ERK1/2 pathway alone resulted in a punctate
staining pattern that was devoid of APPL1 co-staining (Fig. 4.4B).

4.3.5. Serum starvation promotes MTMR2 localization to Rab5 and APPL1 endosomes

In a variety cell types, serum starvation has also been shown to inhibit MAPK
activation [153-155]. Notably, we observed a significant decrease in MTMR2 Ser58
phosphorylation levelswhen cells were grown under low serum \ conditions that also
exhibited low ERK1/2 activation (Fig. 4.3A). We also observed this pattern when we
analyzed endogenous MTMR2 from serum starved cells (Fig. 4.15). Since
MAPKmediated phosphorylation of MTMR2 impedes its targeting to early endosomes,
we postulated that our serum starved conditions would enhance MTMR2 localization to
endosomal compartments due to low MAPK activation. Interestingly, upon serum
starvation conditions we observed significant colocalization of MTMR2 with Rab5
positive endosomes (Fig. 4.5A) (quantitation of the data, Fig. 4.16). This observation
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was also recapitulated at the endogenous level (Fig. 4.17). Furthermore, a subset of
MTMR2 also colocalizes with APPL1 positive endosomes under these low serum
conditions (Fig. 4.5B; Fig. 4.16).
Collectively, our results complement the MTMR2 phospho Ser58 immunoblot analysis
performed under similar conditions while further supporting the hypothesis that MAPKmediated phosphorylation regulates endosome targeting of MTMR2.
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Fig. 4. 5. Serum starvation induces subcellular targeting of MTMR2 to Rab5 and
APPL1-positive endosomes. (A,B) HeLa cells were transiently transfected with
FLAGMTMR2 for 42 hours and analyzed by immunofluorescence microscopy. (A)
Untreated cells (top panel) and serum starved cells (lower panel) were probed for FLAGMTMR2 (red) and Rab5 (green). Serum starvation resulted in an increase in the
colocalization of FLAG-MTMR2 with Rab5- positive endosomes. (B) Cells were probed
with FLAGMTMR2 (red) and APPL1 (green). Serum starvation resulted in an increase in
the colocalization of FLAGMTMR2 with APPL1-positive endosomes. Merged images
display regions of colocalization and are represented in expanded views. Images were
collected using 40Xoil objectives. Arrows indicate regions of colocalization. Scale bars:
15 µm.
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4.3.6. Phosphorylation-deficient MTMR2 at positions Ser58 and Ser631 results in APPL1
endosomal targeting

In an effort to complement our MAPK inhibitor treatments and determine the
relationship with respect to the N-terminal and C-terminal phosphorylation sites of
MTMR2, we generated MTMR2 double phosphorylation site mutants at Ser58 and
Ser631 and examined their ability to colocalize with APPL1 or Rab5. Our previous work
has shown that MTMR2 S58A colocalizes with Rab5 [53], thus we initially analyzed if
MTMR2 S58A could also colocalize with APPL1 (Fig. 4.6A top panel; Fig. 4.18).
Although we observed a significant amount of MTMR2 positive vesicles, MTMR2 did
not display any significant colocalization with APPL1. In contrast, HeLa cells expressing
the double phosphorylation-deficient mutant (S58A/S631A) displayed a punctate pattern
that appeared to be localized just on the inside of the cell periphery but did not colocalize
with Rab5 (Fig. 4.6B; Fig. 4.18). Intriguingly, we instead observed that MTMR2
S58A/S631A strongly colocalized with APPL1, with the colocalized vesicles being
enlarged in comparison to those only positive for APPL1 (Fig. 4.6B, enlarged views;
Table 4.1). Notably, upon mutation of the catalytic residue (S58A/C417S/S631A) this
enlargement did not occur (Fig. 4.19) and these vesicles were comparable in size to those
of APPL1 alone (Table 4.1 B). Quantitative analysis of vesicle area revealed that those
vesicles which were positive for both MTMR2 and APPL1 were enlarged only when
MTMR2 PI(3)P catalytic activity was intact (Table 4.1). These suggestive findings are
consistent with the hypothesis that the phosphatase activity of MTMR2 contributes to the
observed enlargement of MTMR2/APPL1 positive vesicles.
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Importantly, the double phosphorylation mutant recapitulated the observations seen with
the double MAPK inhibitor treatment. Taken together, this is the first report of MTMR2
localizing to APPL1-positive early endosomes; an occurrence that seems to be mediated
by dephosphorylation at position Ser631 of MTMR2.
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Figure 4. 6. Dephosphorylation of Ser58 and Ser631 regulates MTMR2 localization
to APPL1 endosomes. (A,B) HeLa cells were transiently transfected with FLAGMTMR2 phospho-variants for 42 hours and analyzed by immunofluorescence
microscopy. (A) Cells were transfected with S58A or S58A/S631A phospho-variants and
were probed for FLAG-MTMR2 (red) and APPL1 (green). (B) Cells were transfected
with S58A/S631A phospho-variant and probed for FLAG-MTMR2 (red) and endogenous
Rab5 (green). Solid arrows indicate regions of colocalization on enlarged vesicles and
open arrows mark smaller vesicles devoid of colocalization. Regions of interest are
presented in expanded views. Images were collected using 40X oil and 63Xobjectives. Scale
bars: 15 µm.
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4.3.7. Phosphorylation of Ser58 regulates general endosomal association while phosphorylation
of Ser631 regulates endosomal shuttling

We have previously determined that dephosphorylation at Ser58 results in
MTMR2 endosomal targeting; however, it is unclear if dephosphorylation at position
Ser631 is sufficient for endosomal localization. As shown in Fig. 4.7, the S58E/S631A
mutant of MTMR2 lacked any significant punctate pattern, suggesting that
dephosphorylation of Ser631 is not sufficient to mediate endosomal targeting when Ser58
is phosphorylated. In contrast, the S58A/S631E mutant did display the characteristic
punctatestaining pattern and partial colocalization with Rab5 to an extent similar to that
observed with the single point mutations at Ser58 (S58A) (Fig. 4.7A; Fig. 4.20). As
expected, we did not observe any regions of colocalization with APPL1 (Fig. 4.7B).
These results argue that dephosphorylation of Ser58 is sufficient for targeting MTMR2 to
endosomal structures.
We postulated that the partial colocalization with Rab5 may be due to the phosphatase
activity of MTMR2 since many Rab5 effectors require PI(3)P for localizing to Rab5positive endosomes [139-142]. Therefore we created a MTMR2 phosphatase inactive
mutant in the S58A/S631E background and reassessed the ability to colocalize to Rab5positive and APPL1-positive endosomes. As expected, this mutant also did not colocalize
with APPL1 (Fig. 4.7B, bottom panel). However, we observed prominent colocalization
between MTMR2 S58A/C417S/S631E and Rab5 compared to the catalytically active
variant (Fig. 4.7A, bottom panel). Thus, these results further support the notion that
Ser58 must be unphosphorylated for MTMR2 to localize to endosomal structures, while
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phosphorylation at position Ser631 seems to regulate the early endosome subtype
accessible to MTMR2.
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Figure 4.7. Rab5 endosomal targeting of MTMR2 is regulated by dephosphorylation
of Ser58 and phosphorylation of Ser631. (A) HeLa cells were transfected FLAG
MTMR2 phospho-variants for 42 hours and probed for FLAG MTMR2 (red) and Rab5
(green). Loss of catalytic activity (S58A/ C417S/S631E) results in an increase in
MTMR2-Rab5 colocalization. (B) Cells were probed for FLAG-MTMR2 phosphovariants (red) and endogenous APPL1 (green). Closed arrows indicate colocalized
vesicles, open arrows indicate vesicles void of colocalization. Images were collected
using 40X oil and 63X objectives. Scale bars: 15 µm.
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To further define the function of MTMR2 on APPL1-postive early endosomes, we
examined if the S58A/S631A mutant was capable of depleting PI(3)P levels from
endosomal structures. This was accomplished by analyzing the dispersion of a well
characterized PI(3)P binding protein marker, EGFP-2XFYVE. This chimeric protein is
thought to largely localize to Rab5- positive early endosomes and re-distributes to
cytoplasmic structures when PI(3)P is depleted by lipid phosphatases or wortmannin
treatment [146]. MTMR2 S58A/ S631E expression resulted in a significant loss of the
characteristic punctate staining pattern for the PI(3)P marker similar to what we had
observed previously for MTMR2 S58A (Fig. 4.8A, bottom panel) [53]. In contrast,
coexpression of the MTMR2 S58A/S631A mutant with EGFP- 2XFYVE revealed no
effect on the localization of the PI(3)P marker as displayed by the punctate staining
pattern and lack of any colocalization (Fig. 4.8A, top panel). These results suggest that
Ser58 dephosphorylation and Ser631 phosphorylation is necessary for efficient PI(3)P
depletion at Rab5 positive early endosomes.
It is possible that depletion of PI(3)P on APPL1-positive endosomes by MTMR2
S58A/S631A may have not been resolved due to the fact that the EGFP-2XFYVE marker
is enriched on Rab5-positive endosomes. Thus, we proposed that examining the
phosphatase inactive MTMR2 variants would achieve greater sensitivity for establishing
a functional relationship between MTMR2 and APPL1 (Fig. 4.8B; Fig. 4.21). First we
determined that APPL1 endosomes do contain detectable levels of PI(3)P accessible to
the EGFP-2XFYVE marker, albeit at lower levels compared to Rab5-positive endosomes
(Fig. 4.22). Also, the inactive MTMR2 S58A/C417S/S631E mutant (which localizes to
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Rab5-positive endosomes) displayed nearly complete colocalization with the PI(3)P
marker as expected (Fig. 4.8B lower panel). Intriguingly, S58A/C417S/S631A, which
localizes to APPL1 endosomes (Fig. 4.22), displayed a subset of vesicles showing
colocalization with the PI(3)P marker (Fig. 4.8B; Fig. 4.21). This colocalization pattern
is consistent with our working hypothesis that MTMR2 may localize to APPL1- positive
endosomes in order to deplete the low levels of PI(3)P within this proximal early
endosome stage.
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Figure 4. 8. Inducible PI(3)P depletion at early endosomes is dependent on MTMR2
catalytic activity. (A,B) HeLa cells were co-transfected with EGFP-2X FYVE (green) and
FLAG-MTMR2 (red) phospho-variants for 42 hours and analyzed by immunofluorescence
microscopy. (A) MTMR2 dephosphorylation at Ser58 and Ser631 (S58A/S631A) prevents
localization to PI(3)P-rich endosomes (top panel). Expression of MTMR2 S58A/S631E induces
PI(3)P depletion at early endosomes (lower panel). (B) Loss of catalytic activity
(S58A/C417S/S631A) of dephosphorylated MTMR2 results in partial colocalization with PI(3)P
endosomes (top panel). Phosphorylation at Ser631 (S58A/C417S/S631E) localizes to PI(3)P-rich
early endosomes (lower panel). Closed arrows indicate colocalized vesicles, open arrow indicate
vesicles void of colocalization. Images were collected using 40X oil and 63X objectives. Scale
bars: 15 µm.
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4.3.8. MTMR2 localization to APPL1 endosomes increases ERK1/2 activation

Previously we have determined that endosomal targeting of MTMR2 is mediated
through dephosphorylation at Ser58 and subsequently results in enhanced signaling
events particularly with respect to ERK1/2 [53]. Interestingly, it has been demonstrated
that PI(3)P depletion prolongs residency of growth factor receptors within APPL1
endosomes, resulting in extended receptor signaling and activation of key signaling
pathways including ERK1/2 [143]. Considering that dephosphorylation at Ser58 and
Ser631 targets MTMR2 to APPL1-positive endosomes, we postulated that expression of
this double phosphorylation site mutant would further enhance endosomal signaling from
these vesicles.
To test this hypothesis, we examined the activation of ERK1/2 in HEK293 cells
expressing wild type MTMR2, MTMR2 S58A or MTMR2 S58A/S631A which were
stimulated with EGF. Consistent with our previous findings, a reproducible increase in
the phosphorylation of ERK1/2 was observed with cells expressing S58A as compared to
wild-type (Fig. 4.9A). Densitometry analysis revealed an approximate 40% increase in
ERK1/2 activation with S58A compared to wild-type (5-minute time period), which
eventually tapered off back down to levels consistent with wild-type (Fig. 4.9B).
Remarkably, cells transfected with S58A/S631A displayed further enhanced activation of
ERK1/2 compared to S58A. More surprising however, was the duration of sustained
ERK1/2 activation in cells expressing the double phosphorylation mutant of MTMR2
compared to the transient ERK1/2 activation seen with MTMR2 S58A. Accompanying
densitometry analysis revealed that there was nearly a 50% and 80% difference at the 15–
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30 and 60-minute time periods, respectively, for cells expressing S58A/S631A compared
to both wild-type and S58A (Fig. 4.9B). Altogether, these results suggest that the
targeting of MTMR2 to APPL1 endosomes, mediated by dephosphorylation at Ser58 and
Ser631, may enhance the endosomal signaling properties of APPL1- positive endosomes.
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Figure 4. 9. Dephosphorylation of Ser58 and Ser631 elicits sustained ERK1/2
activation. (A) HeLa cells were transfected with FLAG-MTMR2, S58A or S58A/S631A,
serum starved for 30 minutes then treated with 5 ng/ml EGF for the indicated times.
Lysates were immunoblotted (IB) for pERK1/2. Total ERK1/2 levels served as loading
control. Lysates were immunostained with anti-FLAG to confirm equal protein
expression. (B) Relative ERK1/2 phosphorylation levels were quantified by densitometry
using ImageJ and normalized to total ERK1/2 levels. Representative western blots are
shown in A. Means ± s.d. of the results of three independent experiments are shown.
**P< 0.01, ***P<0.001 for the comparisons indicated.
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Figure 4.10. siRNA-mediated depletion of ERK1/2 protein levels reduces MTMR2
Ser58 phosphorylation. HEK 293 cells expressing MTMR2 were transfected with
control scramble siRNA or ERK1/2 siRNA as described in Materials and Methods. Cells
were cultured as described in Materials and Methods then stimulated with EGF for 10
min, lysed and analyzed by immunoblotting. Graphs represent normalized quantitative
immunoblot densitometry data of each indicated antibody probe to their respective αactin loading control. Data represents mean and SEM values from at least n = 3
independent experiments, with ***P<0.001, **P<0.01 or *P<0.05.
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Figure 4.11. Depletion of ERK1/2 expression by siRNA induces subcellular targeting
of FLAG-MTMR2 to punctate regions. (A). HeLa cells were transfected with Scramble
siRNA and ERK1/2 siRNA for 72 h and with FLAG-MTMR2 for 42h and analyzed by
immunoflourescence microscopy. Cells were probed for FLAG-MTMR2 (green) and
pERK1/2 (red). The scale bar represents 15 µm. (B). Bar graph displaying the total
number of puncta between Scramble siRNA and ERK1/2 siRNA using automated
counting in ImageJ. Depletion of ERK1/2 caused a significant depletion in the
phosphorylated ERK1/2 staining. Depletion of phosphorylated ERK1/2 resulted in
approximately 3 fold increase in the total number of FLAG-MTMR2 puncta. (n=30), **
P<0.01, bars ±SD.
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Figure 4.12. Inhibition of ERK1/2 phosphorylation by U0126. Cells were first serum
starved (ss) for 30 min then subsequently treated with U0126 (where indicated), followed
by stimulation with 5 ng/ml EGF for 5 and 30 min at 37°C. Total ERK1/2 served as
loading control to changes in ERK1/2 phosphorylation. Representative western blots are
shown (in main text), bar graph is relative change in pERK1/2, means ± SD of the results
from three independent experiments. ** P ≤ 0.001
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Figure 4.13. Localization analysis of wildtype MTMR2 following MAPK inhibitor
treatment. Using JACoP analysis, scatter plots and correlation coefficients were
determined. (A-D), representative scatter plots of the images in Figure 4. MTMR2
partially localizes with Rab5 following ERK1/2 inhibition, +U (A) with a PC of 0.547
while exhibiting no overlap when combined with JNK1 inhibition, +U+SP (B) with a PC
of 0.200. MTMR2 exhibits no overlap with APPL1 following ERK1/2 inhibition, +U (C)
with a PC of 0.185 while displaying significant co-localization when combined with
JNK1, +U+SP (D) with a PC of 0.854. (E) Representative bar graph of Pearson’s
correlation (PC) whole cell analysis from ten individual cells from three separate
experiments. (n = 30), Error bars ± SD. * P < 0.05; ** P < 0.01
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Figure 4.14. Inhibition of ERK1/2 and p38α results in partial localization of
MTMR2 to Rab5 endosomes. HeLa cells were transiently transfected with wt FLAGMTMR2 for 42 h and analyzed by immunofluorescence microscopy. Cells were treated
with the MEK inhibitor (ERK1/2) (+U) combined with the p38α (+SB) inhibitor and
probed for wt FLAG MTMR2 (red) and endogenous Rab5 (green ) (A) or endogenous
APPL1 (B). Arrows indicate regions of interest and presented in expanded views. Images
were collected using 63x objectives. The scale bar represents 15 µm.
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Figure 4.15. Endogenous MTMR2 Ser58 phosphorylation is influenced by altering
serum conditions. (A) HEK 293 cells were cultured and processed as described in
Materials and Methods, following either serum (10 %; + Serum) or low serum (0.5 %; –
Serum) treatment for approx. 12 h. Both lysate and α-MTMR2 immunoprecipitates were
subjected to immunoblot analysis using the indicated antibodies, with graph (B)
representing normalized quantitative densitometry data to the indicated loading control
(y-axis). Data represents mean and S.D. values from 3 independent experiments.
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Figure 4.16. Localization analysis of FLAG-MTMR2 with Rab5 and APPL1 using
JaCop scatter plots from ImageJ and Pearson correlation coefficient. (A) Scatter plot
analysis of serum starved cells displaying a partial overlap of FLAG-MTMR2 with Rab5
with a PC of 0.520. (B) Representative bar graph of the Pearson’s Correlation between
FLAG-MTMR2 and Rab5 (C) Scatter plot analysis of serum starved cells displaying a
partial overlap of FLAG-MTMR2 with APPL1 with a PC of 0.586. (D) Representative
bar graph of the Pearson’s Correlation between FLAG-MTMR2 and APPL1. (E) Bar
graph displaying the total number of puncta between serum and serum starved cells using
automated counting in ImageJ. Serum starved cells show a significant increase in the total
number of puncta. All data was analyzed from 10 individual cells from 3 individual
experiments. (n=30), ** P<0.01, bars ± SD.
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Figure 4.17. Serum starvation induces subcellular targeting of endogenous MTMR2
to Rab5 positive endosomes. (A) Untreated HeLa cells (top panel) or serum starved cells
(lower panel) probed for endogenous MTMR2 (green) and endogenous Rab5 (red).
Serum starvation resulted in an increase in the colocalization of MTMR2 with Rab5
positive endosomes. Merged images display regions of colocalization and are represented
in expanded views. Images were collected using 40x oil objectives. The scale bar
represents 15 µm. (B). Scatter plot analysis using JaCop scatter plots from ImageJ of
serum starved cells which display a partial overlap of endogenous MTMR2 with Rab5
with a PC of 0.702. (C) Representative bar graph of the Pearson’s Correlation between
endogenous MTMR2 and Rab5 of whole cell analysis of 10 individual cells from 3
individual experiments. (n=30), bars ± SD.
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Figure 4.18. Localization analysis of MTMR2 phospho-mutants and MAPK
inhibitors with endogenous APPL1 and Rab5. Using JACoP analysis, scatter plots and
correlation coefficients were determined. (A-C), representative scatter plots of the images
shown in Figure 6. No overlap between S58A and APPL1 with a PC of 0.097 (A), and a
significant degree of co-localization between S58A/S631A and APPL1 with a PC of
0.773 (B). No overlap between S58A/S631A and Rab5 with a PC of 0.172 (C). (D), Bar
graph of Pearson’s correlation (PC) analysis from ten individual cells from three separate
experiments. (n = 30), Error bars ± SD. *** P ≤ 0.001 compared S58A/S631A with
S58A for APPL1 and S58A/S631A with APPL1 and Rab5
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Figure 4.19. APPL1 vesicle enlargement is dependent on MTMR2 S58A/S631A
catalytic activity. HeLa cells were transiently transfected with FLAG MTMR2
S58A/C417S/S631A (red) then immunostained for endogenous Rab5 or APPL1 (green).
Closed arrow heads indicate regions of co-localization and open arrow heads mark
vesicles devoid of co-localization. Images were collected using 63x objectives. Scale
bar represents 15 µm.
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Figure 4.20. Localization analysis of MTMR2 active and inactive phospho-mutants
with endogenous Rab5 and APPL1. Using JACoP analysis, scatter plots and correlation
coefficients were determined. (A-D), representative scatter plots of the images in Figure
7. (E), Bar graph of Pearson’s correlation (PC) analysis from ten individual cells from
three separate experiments. (n = 30), Error bars ± SD. * P < 0.05 compared
S58A/S631E with Rab5 and APPL1; ** P ≤ 0.01 compared S58A/C417S/S631E with
Rab5 and APPL1
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Figure 4.21. Co-localization analysis of MTMR2 phospho-mutants with EGFP2xFYVE. Using JACoP analysis, scatter plots and correlation coefficients were
determined. (A-C), representative scatter plots of the images shown in Figure 8. MTMR2
S58A/S631A does not co-localize with EGFP-2xFYVE (PC of 0.086) (A), while
S58A/C417S/S631A partially co-localizes with EGFP-2xFYVE (PC of 0.428) (B).
MTMR2 S58A/C417S/S631E displays a high degree of co-localization with EGFP2xFYVE (PC of 0.929) (C). (D) Bar graph of Pearson’s correlation (PC) whole cell
analysis from ten individual cells from three separate experiments. (n = 30), Error bars ±
SD. * P < 0.05 compared S58A/C417S/S631A with S58A/S631A; ** P ≤ 0.01 compared
S58A/C417S/S631E with S58A/C417S/S631A.
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Figure 4.22. Subcellular Localization of PI(3)P on endosomes. HeLa cells were
transfected with EGFP-2xFYVE (green) and immunostained for endogenous Rab5 or
APPL1 (red). Merged images display regions of colocalization and are presented in
expanded views. Closed arrow heads mark regions of colocalization and open arrow
heads mark vesicles devoid of colocalization. Images were collected using 63x
objectives. Scale bar represents 15 µm.
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Table 4.1 Catalytic activity of MTMR2 results in enlargement of APPL1 vesicles when
dephosphorylated at Ser58 and Ser631. HeLa cells were transfected with MTMR2 phosphovariants and analyzed by immunofluorescence microscopy. Cells were left untreated (S58A,
S58A/S631A, S58A/S631E, S58A/C417S/S631A, S58A/C417S/S631E) or treated with MAPK
inhibitors as shown. (A), The data indicates that subcellular localization of MTMR2 to APPL1
vesicles through dephosphorylation at sites Ser58 and Ser631 results in enlargement of MTMR2APPL1 positive vesicles and is dependent on MTMR2 catalytic activity. (B), MTMR2 variants
not localized to APPL1 does not affect vesicle area. The data is representative of the average area
(μ m2) of 10 vesicles from individual cells from 3 independent experiments (n=30) ± S.D.
Vesicle area determination was quantified using ImageJ (NIH). **** P < 0.0001.

159

4.4. Discussion

In recent years, it has become apparent that early endosomes are heterogeneous in
terms of both their protein and phosphoinositol lipid composition on the vesicle surface
[156, 157]. This presumably provides for functional diversity that likely contributes to
differences in cargo destination, endosome maturation rates, and endosomal signaling.
The finding in this study that phospho-isomers of MTMR2 localize to different
endosomal subtypes illustrates the important role of reversible post-translational
modifications in regulating and achieving early endosome heterogeneity. In the case of
MTMR2, our data strongly suggests that Ser58 is the master regulator for the general
endosomal binding capacity of MTMR2, as the phosphomimetic mutation (S58E)
sequestered MTMR2 in the cytoplasm regardless of the phosphorylation status of Ser631.
Meanwhile, phosphorylation of Ser631 seems to regulate early endosomal subtype
destination; if phosphorylated, MTMR2 is targeted to PI(3)P-rich Rab5-positive
endosomes, if unphosphorylated, MTMR2 is targeted to APPL1-positive endosomes. We
are currently employing structural mass spectrometry studies to understand the
mechanistic details of why and how phosphorylation of Ser58 so potently prevents
MTMR2 endosomal localization. We are also interested in examining the mechanisms by
which phosphorylation of the C terminal Ser631 site mediates subtype specificity. Since
MTMR2 possesses multiple protein–protein interaction domains in its C terminus, we
suspect that phosphorylation augments or attenuates the accessibility of these domains
towards accessory molecules that are responsible for recruiting MTMR2 to specific
endosome subtypes.
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There are numerous reports that have described APPL1 and APPL2 as Rab5
effector molecules that colocalize on early endosomes [143, 144, 158]. Moreover, the
dissociation of APPL1 from early endosomes during the conversion of APPL1
endosomes into Rab5/EEA1 early endosomes is mediated by the accumulation of PI(3)P,
and in turn, the recruitment of FYVE domain containing proteins including EEA1.
Therefore, the generation and accumulation of PI(3)P is thought to function as the
molecular switch that controls maturation into the canonical early endosomes. It has also
been shown that EEA1 and APPL1 compete for a limited number of binding sites on
Rab5-positive endosomes [143]. When PI(3)P is depleted, the binding of APPL1 to
Rab5-positive endosomes is dramatically increased, while in contrast, attenuation of
APPL1 association to endosomes by PI(3)P generation allows for proficient stabilization
of EEA1 binding to Rab5 endosomes. This competitive scenario is thus mediated by both
PI(3)P kinases and phosphatases to ultimately regulate the signaling and maturation
properties of early endocytic events transitioning through these particular stages.
Moreover, this effect further transitions to downstream sorting machinery which utilize
PI(3)P binding modules for activity. For example, we recently identified a novel PI(3)P
binding protein, receptor-mediated endocytosis-8 (RME-8), involved in endosomal
sorting decisions and retrograde transport [108]. RME-8 association with early
endosomes was dependent on PI(3)P levels and attenuated by MTMR2 lipid phosphatase
activity exemplifying the importance of phosphoinositol levels in a diversity of
endosomal events.
A surprising result from our study was that MTMR2 S58A/ S631A or stimulated
equivalents colocalized with APPL1 but not Rab5, suggesting that this doubly
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dephosphorylated MTMR2 localizes to APPL1 endosomes that are Rab5-negative. In all
cases, this resulted in enlarged vesicle formation of MTMR2/ APPL1-positive endosomes
when compared to APPL-positive endosomes alone. Importantly, however, when
catalytic activity of MTMR2 was impaired (S58A/C417S/S631A), vesicle size did not
change, remaining comparable to sole APPL1 containing endosomes. One possibility is
that MTMR2/APPL1 endosomes are a distinct endosomal subtype that functions as an
initial platform for downstream signaling events regulated in a PI(3)P fashion. However,
a more likely explanation is that these MTMR2/APPL1 endosomes represent a proximal
endosomal stage that precedes Rab5/APPL1 early endosome formation, potentially as a
means to spatially and temporally control PI(3)P levels which in part regulates the linked
signaling events. The significant increase in ERK1/2 activation upon expression of
MTMR2 S58A/S631A and the observed enlarged MTMR2/ APPL1 endosomes supports
this hypothesis. One possibility is that this effect is due to MTMR2-mediated PI(3)P
depletion that leads to halting or retardation of endosomal maturation, a phenotype which
others have shown to result in endosome enlargement and continued receptor signaling
[159-161]. However, further testing will be needed, as our current results don’t directly
demonstrate PI(3)P depletion on APPL1-positive endosomes. Nonetheless, our findings
are reminiscent of an elegant study by De Camilli and colleagues who used a chimeric
MTM1 inducible system to deplete PI(3)P from EEA1/Rab5 vesicles causing reversion
back into APPL1-positive endosomes. Importantly in this study, these PI(3)P depleted
APPL1 endosomes were also enlarged and displayed increased growth factor signaling,
with enlargement also being dependent on the catalytic activity of MTM1 [143].
Moreover, Larijani and colleagues, who were the first group to use the chimeric MTM1
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inducible system, concluded that PI(3)P depletion resulted in endosomal tubulation rather
than enlargement [162]. Both of these studies however, clearly demonstrated that
depletion of PI(3)P on early endosome compartments acutely compromises endosome
maturation. Analogous to the inducible chimeric MTM1 system, our results highlight
how controlling the PI(3)P phosphatase activity of MTMR2 via reversible
phosphorylation serves as a potent mechanism to regulate the residency time of MTMR2
on these various early endosomal subtypes. MTM1 also possess potential
phosphorylation sites within similar N-terminal and C-terminal regions. It will be
interesting to determine if the subcellular targeting of MTM1 and other MTM family
members are similarly regulated by reversible phosphorylation.
Our discovery that ERK1/2 regulates the phosphorylation of Ser58 is a
compelling finding for a variety of reasons. For one, dephosphorylation of MTMR2 at
position Ser58 leads to MTMR2-mediated depletion of PI(3)P on early endosomes
resulting in an increase in ERK1/2 activation (Fig. 4.9), possibly due to a halt or slowing
in endosomal maturation allowing for increased signaling from the PI(3)P depleted
endosomes. Thus, our working model is that Ser58 phosphorylation by ERK1/2 functions
within a negative feedback loop mechanism that in part may be critical for achieving the
appropriate level of endosomal signaling and maturation rate. Another interesting
observation was the dramatic increase in the duration of ERK1/2 activation in cells
expressing MTMR2 S58A/S631A (Fig. 4.9). A long standing dogma is that the signal
duration can dynamically influence cellular fate [163]. Furthermore, sustained ERK
activation is thought to illicit different biological outcomes compared to transient ERK
activation. For example, differentiation of PC12 cells into sympathetic-like neurons
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requires sustained ERK activation, whereas transient ERK activation induces PC12 cell
proliferation [164, 165]. As is seen in PC12 cells, in most cell types, sustained ERK
activation induces differentiation. However, in Schwann cells, sustained ERK activation
triggers dedifferentiation in response to a variety of environmental cues including
neuronal injury [166, 167]. Schwann cell de-differentiation into a progenitor cell-like
stage is critical for axonal re-growth and is highlighted by extensive demyelination [166].
Schwann cell demyelination is one of the main hallmarks of CMT diseases. Coupled with
the fact that phosphorylation at position Ser58 results in a functionally inactive,
cytoplasmic localized MTMR2, it will be important to investigate if sustained ERK1/2
mediated phosphorylation of MTMR2 plays a role in the pathophysiology of CMT
disease.
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CHAPTER 5
GENERAL CONCLUSIONS, OUTLOOK AND FUTURE WORK
5.1. Identification and characterization of novel PI(3)P binding proteins regulated by
MTMR2

CMT4B1 is a severe demyelinating neuropathy caused by a loss-of-function
mutation on the mtmr2 gene. Unfortunately, the mechanistic details by which the disease
is caused are largely unknown. This task has proven difficult partly due to the poor
understanding of PIP binding domains that specifically interact with the PIP isoforms
targeted by MTMR2. In this study, we utilized a proteomic approach using immobilized
PIP isoforms to identify novel PIP binding proteins. Herein, we identify RME-8 as a
novel PI(3)P binding protein regulated by MTMR2. In particular, our data revealed that
MTMR2 mediated PI(3)P depletion induced attenuation of RME-8 endosomal
localization, suggesting a model in which the localization of RME-8 to endosomal
compartments is spatially mediated by PI(3)P binding and temporally regulated by
MTMR2 activity.
RME-8 is a poorly characterized protein whose function is thought to mediate the
translocation of Hsc70 to early endosomes for clathrin removal during retrograde
transport. Since, RME-8 association with early endosomes occurs in a PI(3)P-dependent
fashion, we further identified the amino acids necessary for PI(3)P binding. The ability of
RME-8 to associate with PI(3)P and early endosomes is largely abolished when residues
Lys17, Trp20, Tyr24, or Arg26 are mutated, resulting in diffused cytoplasmic localization of
RME-8 while maintaining the ability to interact with Hsc70. These amino acids reside
within a region predicted to adopt a pleckstrin homology-like fold located in the N
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terminus of RME-8. More importantly, we also discovered that RME-8 PI(3)P binding
regulates early endosomal clathrin dynamics in addition to altering the steady state
localization of the CI-MPR. These results further emphasize the significance of PI(3)P in
the RME-8-mediated organizational regulation of various endosomal trafficking events,
such as the retrograde transport.
More investigation needs to be done to further study the effect of myotubularins
in endocytic vesicular traffic, and in particular endosomal-to-TGN retrograde transport.
Studies in C. Elegans describe that MTM-6 and MTM-9 lipid phosphatases act as
regulators of MIG-14/Wls trafficking, whose receptors follow the endosome-to-TGN
retrograde transport pathway [168]. Under normal conditions, prior to PI(3)P
dephosphorylation, MTM-6 and MTM-9 form a heterodimer. The direct evidence that
myotubularins regulate retrograde transport was observed in genetic mutants of mtm-6 or
mtm-9 in C. Elegans, which caused severe defects in retrograde-dependent Wnt signaling
[168]. Our results demonstrate that MTMR2 directly regulates the retromer component of
RME-8, which in turn also controls the traffic of acid hydrolase receptors via PI(3)P
binding (Fig 5.1). Thus it would be very insightful to further investigate whether
MTMR2 plays a role in retrograde transport regulation of acid hydrolase receptors, as this
would likely point to a role in regulation of lysosomal biogenesis. Discovering a link
between CMT4B1 and lysosomal biogenesis may allow researchers in the field to
determine if aberrant lysosomal activation contributes to myelin degradation in the
disorder.

171

Figure 5.1. Sorting of the acid hydrolases via mannose 6-phosphate receptors during
normal (left panel) and aberrant (right panel) endosomal retrograde transport from
the early endosomes to the Trans- Golgi- Network. Adapted from Bonifacino, J. S. &
Hurley, J. H. (2008) Retromer, Curr Opin Cell Biol. 20, 427-36.
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Moreover, there are numerous studies suggesting that clathrin and retromer act in
a coordinated successive manner during retrograde transport sorting pathway [84]. Of
note, the hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) has been
shown to associate with both clathrin and the retromer subunit SNX-1 [169, 170]. Once
Hrs binds PI(3)P via its FYVE domain, it helps recruit clathrin to the early endosomes to
form Hrs/clathrin domains, whereby ubiquitinated cargo concentrates prior to being
transferred to the endosome-associated complex required for transport (ESCRT)
machinery for degradation soon after it fuses with lysosomes [169, 171]. Since both Hrs
and RME-8 associate with SNX-1 it is possible that a competition mechanism exists for
access to SNX-1. It is presumed that SNX-1/Hrs and SNX-1/RME-8/Hsc70 complexes
act in an antagonist manner, with the SNX-1/RME-8/Hsc70 complex disassembling
clathrin and promoting cargo sorting via retrograde transport, whereas the SNX-1/Hrs
complex accumulating cargo and promoting degradation via lysosomal degradation.
Furthermore, the competition between Hrs and RME-8 for binding to SNX-1 may
allow switching from clathrin recruitment (SNX-1/Hrs) to clathrin uncoating (SNX1/RME-8/Hsc70), determining the fate of cargo, either to degrade or recycle through
retrograde transport [83]. Hrs and SNX-1 both bind PI(3)P. We are therefore interested in
investigating whether endosomal localization of SNX-1 or Hrs is regulated by MTMR2.
Our preliminary results suggest that while Hrs endosomal localization is not affected by
MTMR2 phosphatase activity, SNX-1 endosomal punctate pattern of localization is
largely abolished in MTMR S58A expressing HeLa cells (data not shown). This data
suggests that MTMR2 targets a pool of PI(3)P rich endosomes that are positive for SNX1 and RME-8, while not affecting the PI(3)P rich endosomes that are Hrs positive. Our
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working model has MTMR2 targeting complexes involved in clathrin uncoating (SNX1/RME-8/Hsc70) rather than clathrin accumulation (SNX-1/Hrs). We thus hypothesize a
role for MTMR2 in cargo recycling via retrograde transport rather than degradation.
While more research is needed to validate these results, we conclude that MTMR2
reversible phosphorylation may serve as a molecular switch to rescue and direct cargo at
a specific subcellular localization by controlling a particular endocytic vesicular traffic
pathway.

5.2. Identification of the mechanism by which MTMR2 reversible phosphorylation
regulates endosomal trafficking events
MTMR2 is a 3-phosphoinositide lipid phosphatase with specificity towards the D3 position of PI(3)P and PI(3,5)P2 lipids enriched on endosomal structures. Recently, we
have shown that phosphorylation of MTMR2 on Ser58 is responsible for its cytoplasmic
sequestration, whereas dephosphorylation targets it to Rab5-positive endosomes. This
results in PI(3)P depletion and an increase in endosomal signaling, in particular ERK1/2
activation. Moreover, we provide evidence that ERK1/2 is the kinase responsible for
phosphorylating MTMR2 at position Ser58, indicating that the endosomal targeting of
MTMR2 is regulated through an ERK1/2 negative feedback mechanism. Surprisingly,
treatment with multiple MAPK inhibitors resulted in a MTMR2 localization shift from
Rab5-positive endosomes to the more proximal APPL1-positive endosomes. This
MTMR2 endosomal shuttling was recapitulated when a double phosphorylation-deficient
mutant (MTMR2 S58A/S631A) was characterized. Further analysis of combinatorial
phospho-mimetic mutants demonstrated that it is the phosphorylation status of Ser58 that
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regulates general endosomal binding and that the phosphorylation status of Ser631
mediates the endosomal shuttling between Rab5 and APPL1 subtypes. Taken together,
these results reveal that MTMR2 compartmentalization and potential subsequent effects
on endosomal maturation and signaling are dynamically regulated through MAPKmediated differential phosphorylation events.
Although mtmr2 gene mutations cause the severe demyelinating neuropathy
CMT4B1, the mechanism by which these mutations produce demyelinating phenotypes
in the peripheral nervous system is still a matter of intense investigation. A major
mechanism active in demyelinating neuropathies is dedifferentiation of myelinating
Schwann cells [172].

During this process, Schwann cells dedifferentiate into an

immature state in response to losing contact with the axon. During this stage, Schwann
cells turn off the myelin program, re-enter the cell cycle and proliferate [172]. A similar
phenomenon occurs following axonal damage, Schwann cells dedifferentiate into
immature cells and start proliferating [172]. Then, they begin to re-differentiate and remyelinate the newly regenerated axons to finalize the regeneration process. It is
presumed that it is the instability of the differentiating and the dedifferentiating signals
that lead to demyelinating neuropathies [172]. One of the key signaling molecules that
induce Schwann cell dedifferentiation and demyelination is ERK1/2 [167, 173-175].
Moreover, studies in mice deficient for the myelin component P0, which is a
model of a CMT subtype, have revealed an increase in the recruitment of demyelinating
macrophages at the nerves. Moreover, it was observed that the accumulation of
demyelinating macrophages was mediated by ERK1/2 dependent MCP-1 chemokine
upregulation, suggesting that ERK signaling pathway plays a significant role not solely in
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triggering the demyelination process, but maintaining it as well. These results are very
intriguing and might explain the mechanistic details behind the demyelinating
neuromuscular physiopathology [176, 177].
In conclusion, there is accumulating evidence indicating a role of ERK1/2 as a
driver of the dedifferentiation and demyelination process in Schwann cells. Moreover,
our results suggest that ERK1/2 down regulates MTMR2’s function in the cell.
Therefore, we believe that it would be imperative to determine the MTMR2
phosphorylation state at different stages of Schwann cell dedifferentiation to gain insight
about MTMR2’s function during this pivotal process. Determining if aberrant ERK
signaling or MTMR2 function hurdles the process of redifferentiation and/or
remyelination might provide crucial insight of our understanding not only of the
regenerative process, but also the signaling pathways that promote inherited peripheral
demyelinating neuropathies.
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